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Abstract 
 
Cancer is the second leading cause of death worldwide and has been over the last decades an 
area of intensive research. Platinum based chemotherapeutics as cisplatin, oxaliplatin or car-
boplatin are used in approximately 50% of all cancer treatments. Due to severe side effects of 
these drugs (e.g. nephrotoxicity, neurotoxicity, nausea, vomiting etc.) and intrinsic or ac-
quired resistance, there is an intensive search for novel drugs to overcome these limitations. In 
the last decade, complexes with metal ions other than platinum, like gallium and ruthenium, 
have been investigated for their anticancer properties. These compounds have a general lower 
toxicity and from the chemical point of view more coordination sites compared to platinum. 
Several ruthenium(III) and gallium(III) complexes (KP46, trismaltolate gallium, KP1019, 
NAMI-A) entered clinical trials and gave promising results. It is supposed, that the active 
species of the Ru(III) drugs are Ru(II) analogues which are obtained by reduction with glu-
tathione inside the tumor cell (“Activation by Reduction”).  
During the last years, the novel class of “piano-stool” configurated Ru(II) arene complexes 
has found considerable interest. The arene ligand stabilizes the Ru(II) central atom and also 
provides an hydrophobic face for the passive transport inside the cell. By modifying the arene 
moiety, the solubility in water changes dramatically and the affinity to nucleobases can be 
tuned. 
4-Pyrones have been used as chelating ligands for a long time, due to their high affinity to-
wards metal ions. 3-Hydroxy-2-methyl-4-pyrone (maltol) is one of the best known com-
pounds of this class, which forms stable and defined complexes with a high number of 2- and 
3-valent metal ions, such as Fe(III), Ga(III), Zn(II), Al(III), Ru(III) etc. and based on of its well-
studied biocompatibility a favorable toxicity profile is suggested.   
Within this Ph.D. thesis, a series of novel Ru(II) arene complexes, bearing a pyrone or thiopy-
rone moiety as chelating ligand, were synthesized and characterized by 1D and 2D NMR 
spectroscopy, FT-IR spectroscopy, mass spectrometry, elemental analysis and, if single crys-
tals were obtained, by X-ray diffraction analysis. The stability in aqueous solution, pKa values 
of the aqua species and the interactions with small biomolecules (e.g. 5’-GMP, and various 
amino acids) were determined. The cytotoxic activity of the complexes towards the human 
cancer cell lines CH1 (ovarian carcinoma), SW480 (colon carcinoma) and A549 (lung carci-
noma) was investigated by using the colorimetric MTT assays, expressed as the IC50 values 
and structure–activity relationships have been derived. 
Zusammenfassung 
 
Krebs ist die zweithäufigste Todesursache weltweit und in den letzten Jahrzehnten wurde 
nach immer neuen Behandlungsmöglichkeiten geforscht. Platinbasierende Zytostatika (Cis-
platin, Carboplatin, Oxaliplatin) werden in ca. 50% aller Chemotherapien verwendet, aber 
wegen starker Nebenwirkungen (Nierenschädigung, Neurotoxizität, Übelkeit, Erbrechen, etc.) 
und Resistenzbildung werden neue Medikamente mit einer höheren Selektivität gegenüber der 
Krebszellen mit einer geringeren Toxizität bei normalen Zellen gesucht. Deswegen steigerte 
sich in den letzten Jahren das Interesse an Metallkomplexen mit anderen Zentralatomen als 
Platin, wie z. B. Ruthenium oder Gallium. Der Vorteil dieser neuen Verbindungen besteht in 
einer geringeren Toxizität und aus der Sicht des Chemikers in der höheren Koordinationszahl 
im Vergleich zu Platin. Eine Serie von Ru(III) und Ga(III) Komplexen (KP46, Trismaltolato-
gallium, KP1019, NAMI-A) befindet sich derzeit in klinischen Studien mit sehr vielverspre-
chenden Resultaten. Es wird vermutet, dass Ru(III) intrazellulär durch Glutathion zur aktiven 
Ru(II) Spezies reduziert wird („Activation by Reduction“ Hypothese). 
Seit einiger Zeit findet die Klasse der Ru(II) Aren Komplexe immer größer werdendes Inte-
resse. Der aromatische Ligand stabilisiert das Ru(II) Zentralatom und bietet eine hydrophobe 
Stelle für den passiven Transport in die Zelle. Durch die Modifikation des Arens kann die 
Löslichkeit der Verbindung und die Affinität zu Nukleobasen stark beeinflusst werden.  
4-Pyrone werden aufgrund ihrer starken Affinität zu Metallionen seit langem als Chelatligan-
den verwendet. Maltol ist ein Vertreter dieser Substanzklasse der mit verschiedensten di- und 
trivalenten Metallionen, wie etwa Fe(III), Ga(III), Zn(II), Al(III), Ru(III), stabile und definierte 
Komplexe bildet und weiters eine hohe Biokompatibilität mit einem bevorzugten Toxizitäts-
profil verbindet. 
Im Rahmen meiner Doktorarbeit wurde eine Serie neuer Ru(II)-Aren Komplexe, mit Pyron- 
und Thiopyronderivaten als Liganden, hergestellt und mittels 1D/2D NMR Spektroskopie, 
FT-IR Spektroskopie, Massenspektrometrie, Elementaranalyse und im Fall von Einkristallen 
mit Kristallstrukturanalyse charakterisiert. Die Stabilität in wässriger Lösung und der pKa 
Wert der reaktiven Aqua-Spezies wurden bestimmt und Untersuchungen bezüglich der Wech-
selwirkungen mit kleinen Biomolekülen (z.B. 5’-GMP und diverse Aminosäuren) durchge-
führt. Die IC50 Werte der Komplexe bezüglich der humanen Krebszelllinien CH1 (Eierstock-
krebs), SW480 (Dickdarmkrebs) und A549 (Lungenkrebs) wurden bestimmt und Struk-
tur/Aktivitäts-Beziehungen abgeleitet.  
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 1. Abbreviations 
 
 
1D  one-dimensional (NMR) 
2D  two-dimensional (NMR) 
AMP  adenosine 5’-mono-phosphate 
brs  broad singlet (NMR) 
°C  degree Celsius 
d  doublet (NMR) 
CDCl3  deuterated chloroform 
CMP  cytidine 5’-monophosphate 
δ  chemical shift 
d6 - DMSO deuterated dimethyl  
sulfoxide 
DNA  2’-deoxyribonucleic acid 
D2O  deuterated water 
e.g.  exempli gratia (for exam-
ple) 
et al.  et alii (and others) 
etc.  et cetera (and other things) 
ESI  electrospray ionization 
g  gram 
h  hour 
Gly  glycine 
GMP  guanosine 5’-
monophosphate 
Hz  hertz 
IR  infrared (spectroscopy) 
J  coupling constant (NMR) 
L-Cys  L-cysteine 
L-His  L-histidine 
L-Met  L-methionine 
m  multiplet (NMR) 
mg  milligram 
min  minute 
µM  micromolar 
mL  milliliter 
mM  millimolar 
mmol  millimol 
m.p.  melting point 
MS  mass spectrometry 
NMR  nuclear magnetic resonance 
(spectroscopy) 
pH  pondus Hydrogenii (power 
of hydrogen) 
pKa  log Ka (acid dissociation 
constant) 
ppm  parts per million 
RNA  ribonucleic acid 
s  singlet (NMR) 
t  triplet (NMR) 
TMP  thymidine 5’-monophosphate 
1
 2. Introduction 
 
2.1. Cancer – General considerations 
 
Cancer is a class of diseases where cells with malignant character grow uncontrolled, fol-
lowed by invasion of healthy tissues and often formation of metastases. Cancer is the second 
most prevalent death cause in the European Union. There were about 3.4 million incident cas-
es of cancer and approximately 1.8 million deaths due to this disease registered in 2008. The 
most common cancers for men are prostate, lung and colorectal cancer and are responsible for 
about 50% of cancer deaths. In the case of women, breast, colorectal and lung cancer are pre-
dominant (Figure 1). 
 
 
Figure 1: Cancer incidence and mortality rates in the EU1 
 
A similar trend is observed in Austria, where cancer causes 25.4% of all deaths. Over the last 
20 years the number of cancer incidents increased by about 28%, whereas the mortality ratio 
                                               
1
 WHO, world cancer report 2008 
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 kept nearly stable (+1%)2. This can be explained by the development of improved cancer the-
rapeutics as well as by the better prevention and early diagnosis.  
 
2.2. Carcinogenesis 
 
Carcinogenesis (Figure 2) deals with the transformation of healthy to malignant cells and is a 
complex and until now not fully understood process over several stages: (i) Initiation, (ii) 
Promotion, (iii) Conversion, (iv) Progression. 
 
Initiation is the first step, where mutagens modify DNA. If the damage is too serious that the 
repair mechanisms of the cell or the programmed cell death (apoptosis) fail, this irreversible 
mutation is given to the next cell generation and proto-oncongenes can be generated, which 
promote cell growth and mitosis. The same result is obtained by mutations of tumor suppres-
sor genes, e.g. the p53 gene. Several severe mutations are necessary for the conversion of 
normal cells in malignant cells3. 
 
Figure 2: Carcinogenesis 
                                               
2
 Statistik Austria, Jahrbuch der Gesundheitsstatistik 2007  
3
 C. Haskell, Cancer Treatment, Academic Press, New York 2008 
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The next step is the promotion by exo- or endogenous parameters (promotors) (alcohol, free 
radicals, hormones,…), which results in proliferation of the initialized cells. The preneoplastic 
cell population with identical mutations is restricted (benign tumor), but able to handicap or-
gans or invade surrounding tissues. This stage is reversible, due to the dependence on a con-
stant presence of the promoter. Additional mutations lead to the formation of malignant cells 
inside the benign tumor. This transformation could also occur directly after initiation and the 
appearance of benign tumors is not required.  The next stage (Progression) is the fast and un-
controlled cell growth, activated by progressors. The tumor invades and damages healthy tis-
sue and metastases are released into the blood or lymph stream.  
 
 
2.3. Different methods of cancer treatment 
 
Due to the fact, that cancer is a class of diseases, there will be no single cure. Various meth-
ods have been developed within the last century. Cancer treatment differs depending on the 
class, the state and the location of the tumor. The age and health state of the patient is impor-
tant as well. The most common approaches for cancer treatment are: 
 
• Surgery: only applicable for primary tumors and localized metastases 
• Radiation therapy: can be used for every solid tumor and localized metastases, but 
damages healthy tissues and has severe side effects like damage of the epithelial sur-
face, swelling as a consequence of inflammation … 
• Chemotherapy: chemicals which harm the cell replication by binding or intercalation 
to DNA, interaction and inhibition of proteins involved in the cell cycle (e.g. topoi-
somerase I and II) 
 
In most cases, cancer is treated by a combination of the above listed methods to increase the 
chance of cure.  
 
4
 2.4. Classes of chemotherapeutics 
 
Chemotherapy is a general term for treating diseases by using pharmaceutical compounds, but 
in general used for substances active in the treatment of cancer. The main targets of chemot-
herapeutics are often DNA or other crucial parameters for cell replication like Topoisomerase 
or inhibition of mitosis. In many cases, the drug interacts with DNA by formation of a cova-
lent bond or by intercalation into the α-helix, which inhibits the DNA transcription and in-
duces cell death. The following classes of compounds are used for clinical treatment4.  
 
• Alkylating agents alkylate DNA and induce strain breaks, cross-linking of DNA, RNA 
and proteins 
o Triazines e.g. Dacarbazine 
o Nitrogen mustards e.g. Cyclophosphamide; Chlorambucil 
o Alkyl sulfonates e.g. Busulfan 
o Nitrosoureas e.g. lomustine, carmustine, streptozocine 
o Platinum(II) or (IV) complexes e.g. Cisplatin, carboplatin, oxaliplatin are of-
ten wrongly referred as alkylating agents. 
 
• Anti-Metabolites mimic essential DNA nucleobases like modified purines or pyrimi-
dines and induce cell cycle arrest 
o Folic acid analogues e.g. methotrexate 
o Pyrimidine analogues e.g. 5-fluorouracil, floxuridine, gemcitabine 
o Purine analogues e.g. Tioguanine, Fludarabine 
 
• Topoisomerase inhibitors: DNA replication and transcription is hindered e.g. topo-
tecan (Topoisomerase I), etoposide (Topoisomerase II) 
 
Other approaches for cancer treatment are for example hormone inhibitors (GnRH - analogs), 
mitosis inhibitors, cytotoxic antibiotics, antibodies, signal transduction and enzyme inhibitors.  
 
                                               
4
 C. M. Haskell, Cancer Treatment, Saunders, Philadelphia 2000 
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 2.5. Metal-based drugs 
 
Metal-based drugs have been used as therapeutic agents since early history and were appli-
cated in their simplest form, as salts. Li2CO3 is an important tool for the treatment of manic 
states and bipolar disorder and is in clinical application since the 1950ies. Lithium carbonate 
is administered orally and has a well established toxicity profile. Arsenic compounds have a 
long history in the treatment of various diseases. Salvarsan was used from 1910 to the 1930ies 
for the treatment of syphilis and was a milestone in the development of metal-based drugs. 
Trisenox (As2O3) was approved in 2000 by the Food and Drug Administration for the treat-
ment of acute promomyelocytic leukemia (APL). Further established metal compounds in 
clinical treatment are: (i) silver nitrate as disinfectant, (ii) mercury salts for their antibacterial 
and antifungal properties, (iii) gold complexes (Auranofin) for the treatment of chronic arthri-
tis, (iv) bismuth salts as antacid and astringent agents, (v) antimony gluconate as antiparasitic 
drug, (vi) gallium salts as anticancer agents5. 
 
Since the discovery of the antineoplastic effect of cisplatin by Barnett Rosenberg6, platinum 
based chemotherapeutics have been a field of intensive research for more than 40 years. Al-
though several thousand compounds have been synthesized, only a small number has entered 
clinical trials7 and only two other compounds, carboplatin and oxaliplatin (Figure 3), are used 
worldwide for the treatment of cancer. These three compounds are used in the treatment of 
approximately 50% of all cancer cases. 
Pt
Cl
Cl
H3N
H3N
O
Pt
ON
N O
OO
O
Pt
O
O
H3N
H3N
H2
H2
 
Figure 3: Platinum compounds used in clinical treatment; from left to right: cisplatin, carboplatin, oxaliplatin  
 
Cisplatin is used for the treatment of small and non-small cell lung cancer, metastatic testicu-
lar tumors, bladder carcinoma, cervical and esophageal cancer. It is one of only few drugs 
with a high curative potential in cancer treatment. The activity profile of carboplatin is very 
                                               
5
 Z. Guo, P. J. Sadler, Adv. Inorg. Chem. 2000, 49, 183. 
6
  Rosenberg, M.; VanCamp, L.; Krigas, T. Nature 1965, 205, 698. 
7
 Galanski, M.; Jakupec, M. J.; Keppler, B. K. Curr. Med. Chem, 2005, 18, 2075. 
6
 similar to cisplatin, but the lower toxicity leads to higher applicable doses. Oxaliplatin is used 
for the treatment of colorectal cancer in combination with 5-fluorouracil. 
 
Nevertheless, it has to be kept in mind that platinum based drugs are only active in a small 
number of tumors and the side effects are severe. Frequently observed are nausea, vomiting, 
nephrotoxicity, neurotoxicity, myelosuppression, tinnitus and ototoxicity. Intrinsic and ac-
quired resistance are also major drawbacks for this class of drugs. To overcome these prob-
lems, the development of novel chemotherapeutics with a different activity profile, mode of 
action, with lower toxicity and higher selectivity is essential for the improved treatment of 
cancer.      
 
As a consequence, complexes with other metal ions than platinum have become an area of 
intensive research. Within our working group, the ruthenium complex KP1019 and the gal-
lium complex KP46 have been synthesized and entered recently clinical trials with promising 
results8. 
 
 
2.6.  Ruthenium complexes  
 
The cytotoxic potential of ruthenium complexes has been found three decades ago and the 
utilization of ruthenium offers several advantages over platinum-based chemotherapy9. First 
of all, ruthenium is stable in different oxidation states (II, III, IV) at physiological conditions 
and also the preparative chemistry is well developed. Ruthenium complexes have an octahe-
dral coordination sphere in contrast to square-planar Pt(II). Ligand substitution kinetics are 
similar to Pt(II) compounds, but tunable due to the strong influence of the coordinated ligands. 
Ruthenium has the ability of mimicking iron, which leads to lower toxic side effects and a 
different mode of action.  
 
The two most famous compounds (Figure 4) are imidazolium [trans-
tetrachloro(dimethylsulfoxide)(imidazole)ruthenate(III)] (NAMI-A) and indazolium [trans-
                                               
8
 F. Lentz, A. Drescher, A. Lindauer, M. Henke, R. A. Hilger, C. G. Hartinger, M. E. Scheulen, C. Dittrich, B. K. 
Keppler, U. Jaehde, Anticancer Drugs 2009, 20, 97. 
9
 R. Margalit, H. B. Gray, M. J. Clarke, L. Podbielski, Chem.-Biol. Interact. 1986, 59, 231. 
7
 tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019). Both complexes adopt octahedral coor-
dination geometry with Ru(III) as central ion. NAMI-A showed marked efficacy against me-
tastases in preclinical models10, whereas KP1019 exhibits excellent activity especially in an 
autochthonous colorectal tumour model that resembles human colon tumors in its histological 
appearance and behavior against chemotherapeutics11. Remarkable is the significantly lower 
toxicity and the general inactivity of platinum-based drugs for this kind of tumors.   
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Figure 4: Ru(III) complexes in clinical trials; NAMI-A (left) and KP1019 (right) 
 
The supposed mode of action of KP1019 involves intravenous application and subsequent 
quick binding to proteins, which is thought to be responsible for the general low toxicity. This 
fast attachment prevents KP1019 of hydrolysis, which would lead to the inactive and insolu-
ble aqua-complex12,13. For platinum chemotherapeutics, the interaction with blood proteins is 
supposed to be an important factor for side effects. The cellular uptake of the KP1019-
transferrin adduct by endocytosis is thought to be enhanced by the increased number of trans-
ferrin receptors, which are expressed by the cancer cell as a consequence of the higher iron 
requirement of malignant cells. After release from the protein, the Ru(III) compound under-
goes in vivo reduction to the kinetically more reactive Ru(II) species by glutathione or other 
biologic reducing agents. This “Activation by Reduction” step was supposed by Clarke three 
decades ago14. The needed reductive micro-environmental conditions for this conversion are 
                                               
10
 Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Curr. Top. Med. Chem. 2004, 4, 1525–1535.   
11
 Berger, M. R.; Garzon, F. T.; Keppler, B. K.; Schmähl, D. Anticancer Res. 1989, 9, 761–766.  
12
 K.-G. Lipponer, E. Vogel, B.K. Keppler, Metal-Based Drugs 1996, 3, 243. 
13
 B. Cebrian-Losantos, E. Reisner, C. R. Kowol, A. Roller, S. Shova, V. A. Arion, B. K. Keppler, Inorg. Chem. 
2008, 47, 6513. 
14
 M. J. Clarke, Met. Ions Biol. Syst. 1980, 11, 231. 
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 formed by the insufficient nutrient and blood supply (hypoxia). DNA does not seem to be the 
main target of KP1019, in contrast to platinum-based chemotherapeutics, although DNA 
damage was observed15. It was found, that the induction of apoptosis could also be explained 
by the intrinsic mitochondrial pathway16, but further investigations are necessary to elucidate 
the major target of KP1019. 
 
As a consequence of the “Activation by reduction” hypothesis, Ru(II) complexes have been 
investigated for their cytotoxic potential. Ruthenium(II) can be easily oxidized and for stabili-
zation of the metal center in oxidation state +2, the coordinating ligands play an important 
role. It is known, that Ru(II) reacts fast with sulfur and nitrogen functionalities, forming stable 
compounds. First, the close analogues of cis- and transplatin cis- and trans-Ru(DMSO)4X2 (X 
= Br, Cl) were synthesized and screened for their antiproliferative activity in C75B1 and 
BD2F1 cancer cell lines (lung carcinoma). The trans isomer was found to be 20-fold more 
active against metastases than the corresponding cis complex17,18.  Bi- and polypyridyl Ru(II) 
complexes have been investigated intensively and a large number of applications, related to 
the well documented photophysical and electrochemical properties, have been established. 
The use of typically commercially available polypyridyl ligands like 2,2’-bipyridine (bpy), 
1,10-phenanthroline (phen) and 2,2’:6’2’’-terpyridine (terpy) yields highly stable Ru(II) com-
plexes. The interaction with DNA or other biomolecules have been investigated for this class 
of compounds for more than 20 years and it depends strongly on the type of the polypyridyl 
chelate. The complex [Ru(bpy)3]2+ shows only weak interaction with DNA (mainly electro-
static), while the interaction of [Ru(phen)3]2+ is much stronger19.  Another reported interaction 
with DNA of this class of complexes is intercalation, which depends on the size of the aro-
matic ring system of the polypyridyl ligands. The complex [Ru(bpy)2(dppz)]2+ (dppz = 
dipyrido [3,2-a:2’,3’-c]-phenazine) is luminescent when intercalated into DNA and used 
therefore as a light switching probe, whereas the complex [Ru(bpy)(dpq)]2+ (dpq =dipyrido 
[3,2-d:2c’,3c’-f] quinoxaline) does not show this behavior.  
                                               
15
 S. Kapitza, M. A. Jakupec, M. Uhl, B. K. Keppler, B. Mariam, Cancer Lett. 2005, 226, 115. 
16
 S. Kapitza, M. Pongratz, M. A. Jacubec, P. Heffeter, W. Berger, L. Lackinger, B. K. Keppler, B. Marian, J. 
Cancer. Res. Clin. Oncol. 2005, 46, 472.  
17
 E. Alessio, G. Mestroni, G. Nardin, W. M. Attia, M. Calligaris, G. Sava, S. Zorzet, Inorg. Chem. 1988, 27, 
4099. 
18
 G. Sava, S. Pacor, S. Zorzet, E. Alessio, G. Mestroni, Pharmacol. Res. 1989, 21, 617. 
19
 J. M. Kelly, A. B. Tossi, D.J. McConnel, C. Oh Uigin, Nucl.  Acids Res., 1985, 13, 6017. 
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2.7. Overview of ruthenium(II)-arene complexes 
 
Iron(II) has similar chemical and physical properties as ruthenium(II) and therefore, stabiliza-
tion can also be easily achieved for Ru(II) by η6-coordination of aromatic moieties, which 
leads to half sandwich complexes. The Ru(II) center adopts the so called “piano-stool” con-
figuration, where the aromatic ring forms the seat and the remaining three ligands the legs 
(Figure 5).  
 
X
Y
Ru
z
R
 
Figure 5: General formula of Ru(II) complexes with “piano-stool“ configuration 
 
This conformation offers the opportunity of derivatization at the arene moiety and the applica-
tion of various mono- or bidentate ligands. In general, at least one halide is coordinated to the 
ruthenium, because the aquation, which leads to the formation of a highly reactive aqua spe-
cies, seems to be essential for the activity, though also inert complexes with anticancer prop-
erties have been reported. This conversion to a charged complex is responsible for the good 
aqueous solubility, which is also an important factor for biological studies and possible clini-
cal applications. Insertion of the arene moiety has important effects on the physical and chem-
ical properties: (i) it offers a hydrophobic face which facilitates the passive transport via dif-
fusion through the cell membrane and gives the possibility of intercalation with the DNA 
double-strand; (ii) it has a big influence on the ligand exchange kinetics and protein binding 
ability; (iii) it is inert toward ligand exchange reactions, but it is flexible site for derivatiza-
tion20.  
 
This class of organometallic ruthenium compounds has been investigated for more than twen-
ty years. One of the first reported complexes was [Ru(C6H6)(DMSO)Cl2] (Figure 6). This 
complex shows strong inhibition of topoisomerase II, which is essential for structural organi-
                                               
20
 M. J. Clarke, Coord. Chem. Rev., 2003, 236, 209. 
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 zation of the mitotic chromosomal scaffold during the cell replication process21. The coordina-
tion of PTA (1,3,5-triaza-7-phosphatricyclo[3.3.1.]decane) instead of DMSO yields the so 
called RAPTA complexes (Figure 6). Dyson et al. have shown, that this ligand exchange 
leads to largely increased aqueous solubility, interesting antimetastatic activities with high 
selectivity next to a low general toxicity. The PTA ligand is supposed to be responsible for 
the observed selectivity.  It has been shown, that methylation of one PTA nitrogen leads to a 
large increase of toxicity22. The replacement of the chlorido ligands by oxalate or cyclobu-
tane-1,1-dicarboxylate gives analogues of oxali- and carboplatin, which show minor influence 
on the biological activity23.    
 
Cl
Ru
Cl N
N
N
PDMSOCl
RuCl
Cl
Ru
Cl P OO
O
O
O
O
 
Figure 6: from left to right: [Ru(C6H6)(DMSO)Cl2], RAPTA-C, KP1558 
 
Ru(II) cymene complexes have been prepared, wherein the PTA has been replaced by 3,5,6-
bicyclophosphite-α-D-glucofuranoside ligands. It has been shown that the cytotoxic activity 
can be tuned by the lipophilicity of the alkyl moiety of the phosphites. The ruthenium com-
plex KP1558 (Figure 6) has shown among the tested derivatives the highest cytotoxic activity 
towards different cancer cell lines24. Hydrolysis of these P-sugar containing Ru(II) complexes 
leads to the cleavage of one P-O bond. This degradation process can be inhibited by addition 
of sodium chloride, due to the reversibility of the first hydrolysis step of the Ru(II) center. 
 
The complexes [Ru(η6-p-cymene)(X)(Y)(Z)] (X,Y or Z = halide, acetonitrile or isonicotin-
amide) with three monodentate ligands, have no significant activity against A2780 cancer 
cells. This lack of cytotoxicity can be explained by their high reactivity, which leads to fast 
                                               
21
 Y.N.V. Gopal, D. Jayaraju, A.K. Kondapi, Biochemistry 1999, 38, 4382 
22
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23
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24
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 interaction with small biomolecules and potentially deactivates them before reaching the cel-
lular target25. Therefore, organometallic compounds of the general formula [Ru(η6-
arene)(en)X] (Figure 7, arene = benzene or derivatives of benzene, en = ethylenediamine or 
derivatives, X = a halide), have been investigated by Sadler et al and it has been shown, that 
the coordination of the chelating ligand ethylenediamine leads to lower reactivity compared to 
monodentate ligands and  interesting biological and chemical properties was observed26.  
NH2
RuN Cl
H2
benzene biphenyl p-cymene
dihydroanthracene tetrahydroanthracene
Ar
 
Figure 7: Ru(II) arene complexes (by Sadler et al.) with various arene ligands 
 
The cytotoxic activity of these complexes against the human ovarian cancer cells A2780 de-
pends on the size of the coordinated arene and benzene showed the lowest and tetrahydroan-
thracene the highest effect (Table 1).   
 
Arene / Pt compound X Y Z IC50 (µM) 
p-Cymene isonicotineamide Cl Cl >150 
p-Cymene en Cl 10 ± 1.1 
Benzene en Cl 17 ± 8.3 
Tetrahydroanthracene en Cl 2 ± 0.4 
Carboplatin    6 ± 0.7 
Cisplatin    0.6 ± 0.06 
Table 1: IC50 values against A2780 cancer cells of Ru(II) arene complexes with the general formula [Ru(η6-
arene)(X)(Y)(Z)] compared to cis- and carboplatin 
 
                                               
25
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26
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 It has been shown, that hydrolysis plays an important role for the cytotoxic activity of some 
metal based drugs27,28. The halido complexes often act as prodrugs and are activated by hy-
drolysis. Under physiological conditions, the aqua species react rapidly to biomolecules, 
which influences strongly pharmacodynamics and pharmacokinetics. The interaction with 
blood proteins, DNA (components) or small biomolecules has a protective effect and de-
creases the rate of degradation or side product formation29. In the case of Ru(II), the formation 
of the highly reactive aqua complex proceeds via a dissociative process, the leaving group 
(normally the halide) is cleaved off, leading to a 16 electron complex, followed by interaction 
with the solvent molecule, yielding in an activated 18 electron aqua complex.  
 
Next to the increased cytotoxicity by application of chelating ligands, another interesting fea-
ture for these group of Ru(II) arene complexes has been reported30. The complex [Ru(η6-
biphenyl)(en)Cl]+ was found to possess high selectivity towards small biomolecules. This 
compound binds selectively towards the N7 of guanosine, to N3 of thymidine and to N1 and 
N7 of inosine. Hence, no coordination towards adenosine and only weak interaction with N3 
of cytidine was observed. Furthermore, the reactivity at physiological pH decreases in the 
order G(N7) > I(N7) > I(N1), T(N3) > C(N3) > A(N7), A (N1). Therefore, “piano-stool” Ru(II) 
complexes are much more selective than the square-planar Pt(II) compounds. The interaction 
with nucleotides such as 5’-GMP (DNA building block and model for interactions with Pt(II) 
complexes) has been investigated and again selective binding towards N7 was found, simi-
larly to studies with nucleosides. In competition studies with 5’-AMP, 5’-CMP and 5’-TMP 
only the 5’-GMP adduct was observed.  
 
The type of chelating ligand plays an important role and has a strong influence on the chemi-
cal, physical and biological properties of Ru(II) compounds. The exchange of ethylenediamine 
by acetylacetonate (acac) leads to neutral complexes (Figure 8), which have an increased elec-
tron density of the Ru(II) center, which facilitates ligand exchange and hydrolysis processes31. 
The solubility of these compounds is increased, due to the formation of the better soluble and 
                                               
27
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 charged aqua complexes. Furthermore, the before mentioned selectivity towards nucleobases 
is changed. The complex [Ru(η6-p-cymene)(acac)Cl] shows higher affinity towards adenine 
than to guanine. These results give access to novel Ru(II) complexes with different affinities 
and therefore possibilities of tuning the activity of organometallic ruthenium drugs.   
N
O
O
Ru Cl
R
O
RuO Cl
R = Me, Pr, Phenyl,o-C6H4COO2Me
 
Figure 8: left: [Ru(cym)(acac)Cl)]; right: 3-hydroxy-2-methyl-4-pyridone Ru(II) cymene complexes 
 
During the last years, the main target of novel derivatives was the modification of the arene 
moiety, while the chelating ligand kept very simple and purchasable. Severin et al. were the 
first, who synthesized Ru(II) cymene complexes bearing 4-pyridones as chelating ligands32 
(Figure 8), but they focused their investigations on the catalytic properties and not on the anti-
cancer potential. Recently, a series of novel 4-pyridone derived chelating ligands and their 
Ru(II) complexes have been prepared. Investigations have shown that the coordination of py-
ridone moieties leads to highly active compounds with interesting biochemical features (Fig-
ure 9)33.  
N
O
O
R''R'
N
O
O
R''R'
Ru
Ru
X
Cl
R'  = H, -CH3
R'' = -CH3, H
n   = 2,3,4,6,8,12
X = Cl, Br, I 
( )
n
 
Figure 9:Dinuclear pyridone based Ru(II) cymene complexes  
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The lipophilicity of the 3-hydroxy-2-methyl-4-pyridone derived chloro complexes, the corre-
sponding IC50 and log P values are shown in Table 2. It can be seen, that the cytotoxic activity 
correlates with the lipophilicity and can be tuned by increasing the length of the aliphatic 
chain between the two pyridones34. The observed IC50 values are in the same dimension as 
established Pt(II) anticancer drugs. These complexes undergo rapid hydrolysis to the more 
reactive aqua species and form rapidly adducts with DNA and model nucleotides, but no reac-
tion with the small proteins cytochrome c or ubiquitine was observed35. The pKa values are in 
the same range (~ 9.70) as known for other Ru(II) complexes.  
 
IC50 [µM] n log P 
SW480 A2780 
2 -1.42 76 ± 4 84 ± 3 
3 -1.39 62 ± 14 25 ± 2 
4 -1.33 28 ± 1 41 ± 2 
6 -1.36 26 ± 8 30 ± 6 
8 -1.28 2.5 ± 0.2 5.7 ± 0.5 
12 -0.56 0.29 ± 0.05 1.5 ± 0.3 
 
Table 2: log P and IC50 values of dinuclear Ru(II) cymene complexes 
 
Additional, mono and dinuclear Ru(II) cymene complexes derived from ethylmaltol and allo-
maltol, based are currently under investigation36,37. 
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 2.8. 4-Pyr(id)ones as chelating ligands 
 
4-Pyridones and their close analogues 4-pyrones are widely used as chelating ligands due to 
their high affinity towards a large range of di- and trivalent metal ions38, which results in high-
ly stable complexes. This ability can be explained by the pseudo-aromatic character of the 
ring system (Figure 10).   
X
O
OH
X
O
OH
+
X = N-R,O
 
Figure 10: Mesomeric forms of 3-hydroxy-4-pyr(id)one 
 
The conversion of pyrones to the corresponding pyridones can be performed easily and was 
described by Harris et al39. It has been shown, that protection of the hydroxyl group via ben-
zylation facilitates the reaction and the pH value of the reaction (~12) is essential for high 
yield. Cleavage of the benzyl group via hydrogenation affords the desired 4-pyridones. This 
synthetic route enabled a whole series of novel 4-pyridone-based chelating ligands40,41. It was 
found, that 3-hydroxy-4-pyridones have a strong affinity towards iron42 and can therefore be 
used as regulating agent for iron overload disorders.  
 
N
O
OH
N
N
OH
O
O
H
NH2
OH
O
O
HOH
O
N
NN
OH OH
O
OH
 
Figure 11: Compounds used for clinical treatment of iron overload. From left to right: Deferiprone (L1 or 
CP20), Desferasirox (Exjade or ICL670) and Desferoxamin (Desferal) 
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 Deferiprone (1,2-dimethyl-3-hydroxypyrid-4-one)  (Figure 11) was synthesized by Kontoghi-
orghes et al. in the early 1980ies43 and is in clinical application since 2000 in Europe. The 
bidentate ligand forms 1:3 iron chelate complexes and it was found to be relatively non-toxic 
even at high doses (200 mg/kg). Deferiprone was the first drug for the treatment of iron over-
load that could be administered orally, furthermore the high selectivity towards iron is note-
worthy. No significant increase in excretion of Cu, Zn, Mg, or Ca was detected44.  One major 
disadvantage of Deferiprone is the fast inactivation by phase II metabolism (glucuronida-
tion)45. Around 85% of the administered dose is recovered as the converted O-glucuronid in 
the urine. These insights in the deferiprone metabolism led to the synthesis of novel 4-
hydroxypyridones, which do not undergo this inactivation.46 In general, pyridones are used to 
remove metal ions and restore metal overload disorders; pyrone-based complexes act as metal 
source, due to their weaker bidentate binding.   
 
The most common 4-pyrones are shown in Figure 12 and are generally characterized by their 
synthetic versatility. Derivatization at positions 2, 5 and 6 of the ring system and conversion 
to 4-pyridones can be easily accomplished. 4-Pyrones form thermodynamically stable com-
plexes at physiological pH values47.   
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Figure 12: Most common and best studied 4-pyrone derivatives; from left to right: Pyromeconic acid, maltol, 
ethylmaltol, kojic acid, allomaltol 
 
3-Hydroxy-2-methyl-4-pyrone (maltol) is one of the best studied compounds of this class and 
is known for its biocompatibility and favorable toxicity profile. It is used as food additive to 
impart the malty taste and aroma into bread, beer, cakes, etc. Next to its application in food 
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 industry, the maltol derived metal complexes with a series of two- and trivalent ions (Ga(III), 
Zn(II), Al(III), V(IV), etc.) have been investigated over the last decades.  
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Figure 13: Maltol derived complexes under clinical investigations; from left to right: [Ga(Mal)3], [VO(Mal)2]. 
 
Gallium citrate is used since the 1960’s as a soft tumor imaging agent48, but in the last dec-
ades, the focus shifted towards its coordination compounds, since antineoplastic abilities of 
GaCl3 and Ga(NO3)3 were observed. In contrast to the early investigated gallium salts, 
[Ga(Mal)3] (Figure 13) can be administered orally, has a higher bioavailability49, due to stabi-
lization towards hydrolysis, which is the major hindrance for absorption, and less side effects.  
 
Another example to increase the metal uptake by coordination is the 
bis(maltolato)oxovanadium(IV) complex (Figure 13), which is the first vanadium-based insu-
lin enhancing compound, due to the ability of vanadium ions to mimic insulin in vivo50 and in 
vitro51. The anti-diabetic potential of this complex is significantly higher than of the sodium 
vanadate salt and is currently tested in clinical trials52 (together with the ethylmaltol ana-
logue).  
 
Although pyrone complexes have been investigated intensively over the last decades, only the 
organometallic compound [Ru(arene)(Mal)Cl] has been tested for its anticancer activity and 
there is still a need for further investigations on the potential of this class of compounds.  
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 The conversion of 3-hydroxy-4-pyr(id)ones to the corresponding thio compound has been 
described in literature and the most common are (i) addition of 1 eq Lawesson’s reagent53 and  
the (ii) reaction with an excess of P4S1054 under various conditions55. It has been shown, that 
the reaction of two equivalents of Lawesson’s reagent with 4-pyrones leads to highly interest-
ing dithiopyrones56.  
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S
OH
 
Figure 14: 3-Hydroxy-4-thiopyr(id)ones; from left to right: Thiopyromeconic acid, thiomaltol, thioethylmaltol, 
3-hydroxy-1,2-dimethylpyridin-4(1H)-thione 
 
3-Hydroxy-4-thiopyr(id)ones (Figure 14) are a new class of soft chelating agents and their 
metal complexes are under intensive investigations. Coordination compounds with Ga3+ and 
Ho3+ may be used as contrast agents for MRI imaging54. The corresponding Zn2+ and VO2+ 
complexes showed encouraging in vitro results as anti-diabetic agents57.  
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 3. Published results 
 
3.1. Tuning the anticancer activity of maltol derived ruthenium 
complexes by derivatization of the 3-hydroxy-4-pyrone moiety 
Journal of Organometallic Chemistry, 2009, 694, 922-929 
 
Graphical Abstract 
 
 
 
Organometallic ruthenium(II) complexes based on maltol-derived ligands were synthesized 
and their hydrolysis behavior, reaction to the DNA model 5’-GMP, and anticancer activity 
against human tumor cell lines was tested. Promising anticancer activity was observed, with 
the lipophilicity of the compounds appearing to be the determining parameter of anticancer 
activity.  
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Platinum complexes play an important role in the treatment of
cancer and are included into ca. 50% of the therapeutic schemes [1].
Due to severe side effects, high toxicity, limited activity in common
tumor types and tumor resistance, non-platinum complexes are
undergoing intensive research as chemotherapeutics and also as
radiodiagnostics [2–7]. Ruthenium compounds are the most
widely developed alternatives, and (H2Ind) trans-[RuCl4(HInd)2]
(KP1019, HInd = indazole; Fig. 1) and (H2Im) trans-[RuCl4(DMSO)-
(HIm)] (NAMI-A, HIm = imidazole) have entered clinical trials
[4,8,9]. Both compounds exhibit only low side effects, which might
be due to selective uptake via the transferrin cycle [10–15] and/or
activation by reduction [16] in the reductive environment typical
of neoplastic tissue.
More recently stable organometallic compounds moved into
the focus of interest [5]. Beside, for example, titanium, iron andAll rights reserved.
Vienna, Institute of Inorganic
a. Tel.: +43 1 4277 52609; fax:
(C.G. Hartinger), alex.nazarov
21gold compounds [17–19], some of which underwent clinical trials,
Ru(II) species, such as RAPTA type complexes, have been observed
to exhibit anticancer activity, tunable by careful selection of the li-
gand sphere [3,20–32]. These studies resulted in compounds with
interesting modes of action, for example potentially targeting ki-
nases [25,29,30], or drug resistance pathways [27,33] and light
activated systems [34,35], and a number of encouraging in vivo
studies have been reported [3,5,21,22,36,37]. More recently, dinu-
clear pyridinone-based Ru(II) complexes, such as PyrRu122 (Fig. 1),
were observed to exhibit increased cytotoxicity due to jointly act-
ing Ru(II)-arene moieties [31,32,38]. By varying the spacer length
between the two ruthenium centers, compounds with mild to high
cytotoxicity were obtained. Recent studies on their DNA binding
properties revealed different modes of action for compounds only
varying in the length of the spacer between the Ru(II)-arene frag-
ments [31,32,38]. Other maltol-derived compounds have proven
medicinal potential in the treatment of b-thalassemia and diabetes,
and as radiodiagnostics [39] and, when coordinated to a Ga(III)
center, in chemotherapy [2], or in form of a VO(maltolato) complex
as a medication against diabetes type II [40,41].
The coordination ability of maltol-derived ligands with particu-
lar afﬁnities for divalent and trivalent metal ions allows very stable
complexes to be prepared [31,32,42–45], which can easily be
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Fig. 2. 1H NMR of 3d in (a) CDCl3 and (b) D2O.
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Fig. 1. Structural formulae of the ruthenium anticancer drug candidates KP1019,
NAMI-A, RAPTA-C, Ru-maltol and PyrRun2.
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drophobicity, etc.
In the present work, the synthesis of mononuclear Ru(II)-arene
mplexes with novel maltol-derived ligands is reported. The sub-
itution pattern of the aryl part of the ligand was found to be cru-
al for controlling both the in vitro anticancer activity and complex
lubility.
Results and discussion
1. Synthesis and characterization of the Ru(II)-p-cymene complexes
The synthesis of the precursor allomaltol 1 was performed in
o steps, starting form kojic acid by reaction with thionylchloride
llowed by the reduction with zinc under acidic conditions
cheme 1) [46]. Due to the higher reactivity of position 2 com-
red to 5 in the pyrone ring of 1, functionalization can easily beO
O
Cl
O
O
R1
SOCl2
[RuCl2(cym)]2
O
O
OH
HO
O
O
OH
R2
R1 R3
O
Ru Cl
3a-e
Scheme 1. Synthesis of pyrone-based ligands an
22hieved in a similar fashion to the aldol reaction. Compound 1
as deprotonated with NaOH, and the anionic species obtained
as reacted immediately with the corresponding aldehyde, yield-
g ligands 2a–e after addition of HCl and recrystallization (yield
–90%). The reaction occurs only in sufﬁcient yield at pH 10.5.
e air and light stable complexes (>1 year) 3a–e were obtained
deprotonation of the corresponding ligand with sodium meth-
ide and addition of the bis[dichlorido(g6-p-cymene)ruthe-
um(II)]. A slight excess of ligand (10%) was added in order to
cilitate puriﬁcation, and all complexes were obtained in good
eld (52–73%).
The compounds were characterized by IR and 1D and 2D NMR
ectroscopy, mass spectrometry and elemental analysis. All com-
exes possess two stereogenic centers and were isolated as mix-
res of two diastereomers (R/R, S/S and R/S, S/R), as observed by
MR spectroscopy in aprotic solvents, where both forms are distin-
ishable. The separation of the diastereomers by fractional crys-
llization or chromatography was not successful. As a
presentative example, the 1H NMR of 3d in CDCl3 and in D2O is
own in Fig. 2. In CDCl3 two sets of signals are observed for the
drogens of the coordinated arene ring and for the m-ﬂuoro
bstituted phenyl group. In D2O, the spectrum comprises a singleO
O
OH
NaOH / H2O
R2
R1
R3
O
OH
OH
R2
R3
OH
1
2a
2b
2c
2d
2e
R1 = R2 = R3 = H
R1 = R3 = H, R2 = NO2
R1 = R3 = H, R2 = F
R1 = R2 = H, R3 = F
R1 = R2 = R3 = OCH3
2a-e
Zn/HCl
H2O
d their ruthenium(II)-arene complexes.
Table 1
Selected bond lengths (Å) and angles () of 3b and comparisons with the dinuclear
complex PyrRu62 and the structurally related Ru-maltol complex chlorido[3-(oxo-jO)-
2-methyl-4-pyronato-jO4](g6-p-cymene)ruthenium(II).
3b PyrRu62
a Ru-maltolb
Ru–Cl 2.4310(4) 2.4186(10) 2.4329(5)
Ru–O1 2.1179(10) 2.101(3) 2.1035(13)
Ru–O2 2.0766(10) 2.074(3) 2.0901(13)
O1–Ru–O2 78.82(4) 79.63(11) 78.79(5)
O1–Ru–Cl 83.35(3) 83.90(8) 83.42(4)
Cl–Ru–O2 85.51(3) 85.11(8) 85.89(4)
a From Ref. [31].
b From Ref. [28].
Table 2
Solubility in PBS and IC50 values of 3a–e and of Ru-maltol in the human cancer cell
lines CH1, SW480 and A549.
Compound Solubility (mg/mL) IC50 (lM)
CH1 SW480 A549
3a 0.25 50 ± 9 67 ± 10 172 ± 5
3b Insoluble – – –
3c 0.1 24 ± 4 44 ± 10 98 ± 4
3d 0.1 29 ± 2 57 ± 8 138 ± 6
3e 1 48± 6 84 ± 7 220 ± 14
Ru-maltol >10 >100 >100 –
924 W. Kandioller et al. / Journal of Organometallic Chemistry 694 (2009) 922–929set of signals, presumably due to fast inversion of the metal center,
leading to epimerization of the diastereomers [47,48]. The 1H NMR
signal of the OH proton was observed to be split in aprotic solvents
into two doublets with Dd = 0.2 ppm, which may be due to the for-
mation of a hydrogen bond between the aliphatic –OH group of the
ligand and the coordinated alcoholate of the pyrone ring (Fig. 2).
The IR spectra of the ligands 2a–e show C@O, C@C and C–O
stretching bands at 1654–1120 cm1 [49]. The O–H stretching
bands were observed as broad bands in the range 3420–
3280 cm1. The spectra of 3a–d contained four bands in the region
of 1610–1460 cm1, which are typical for maltolato complexes
[50,51]. Upon complexation the C@O stretching bands appear
shifted by 40 cm1 to lower wavenumbers. In the case of 3e strong
overlapping of the latter signals with those assignable to the meth-
oxy groups was observed. In the spectra of the complexes the
bands attributed to the OH stretching are in the range 3400–
3340 cm1 and are of signiﬁcantly lower intensity due to deproto-
nation and coordination of one of the OH groups to the Ru centers.
ESI mass spectra of 3a–e were recorded in methanol in the po-
sitive ion mode. For all compounds the most abundant peaks were
assigned to [MCl]+ ions, which had the appropriate ruthenium
isotopic pattern.
2.2. Crystal structure determination
The molecular structure of 3b was determined by X-ray diffrac-
tion analysis (Fig. 3), and the metal center was found to adopt the
expected pseudo-octahedral ‘‘piano-stool” geometry. In the phenyl
substituted maltolato complex 3b and PyrRu62 a short and a long
Ru–O bond have been observed (Table 1), whereas in chlorido-
[3-(oxo-jO)-2-methyl-4-pyridinonato-jO4](g6-p-cymene)ruthe-
nium(II) (Ru-maltol, Fig. 1) the two Ru–O bond lengths are almost
identical. This observation might be explained by a lengthening of
the Ru–O2 bond in the Ru-maltol complex due to the involvement
of this oxygen donor atom in a strong intermolecular H-bond (do-
nor–acceptor distance of 2.805(2) Å, and a donor–hydrogen–accep-
tor angle of 174). The Ru–Cl bond length in 3b of 2.4310(4) Å is
similar to that in Ru-maltol, whereas the bond observed for the
pyridinone complex PyrRu62 is slightly shorter [31]. Although the
Ru–Cl bond lenghts in the above mentioned structures are very dif-
ferent, the rate of hydrolysis is rapid in all cases (see below).
2.3. Hydrolysis, pKa and GMP binding
Due to the low solubility of 3a–e in water (Table 2), all NMR
experiments on the hydrolytic stability were performed in a 5%Fig. 3. ORTEP plot of the molecular structure of 3b at 50% probability level.
23DMSO-d6/D2O solution. Coordination of DMSO to the ruthenium
center was not observed (data not shown). NMR spectra of the
complexes with and without addition of AgNO3 (used to remove
the chlorido ligand) are identical, indicating that the hydrolysis
proceeds immediately upon dissolving in water. The aqua com-
plexes are stable in aqueous solution, whereas the Ru-maltol com-
plex reacts to form a dimeric ruthenium compound [28], indicating
that the hydroxyl-methyl-aryl substituent in position 2 of the pyr-
one ring inhibits the formation of dimeric species.
The pKa values of the aqua complexes of 3a–e were estimated
by titration with NaOD to afford the corresponding hydroxido
compounds by monitoring the deprotonation process by 1H NMR
spectroscopy (Table 3). To generate the aqua species, the com-
plexes were dissolved in D2O containing 5% DMSO-d6. The chemi-
cal shifts of the Arcym-H2/H6 proton signal of the arene ring (e.g.,
from 5.75 ppm at pH 3.21 to 5.49 at pH 11.00 for 3c) were plotted
against the pD value. The pKa values (in D2O) were determined
from the inﬂection point of the sigmoid curve (see Fig. 4 for the
titration curve of 3c) and corrected for the difference between
D2O and water to yield the pKa (using Eq. (1), see Section 4). The
pKa values of 3a–e were determined to be between 8.99 and
9.80, with the substitution of the aryl moiety of the ligand having
only a minor inﬂuence. The pKa values are similar to those of the
parent compound Ru-maltol (pKa 9.23) [28] and the dinuclear
pyridinone-type ruthenium arene complexes (pKa 9.60–9.83) [31].
The reaction of 3a–e with the DNA model compound 50-GMP
was investigated by 1H and 31P NMR spectroscopy to evaluate
the potential of DNA as an intracellular target, as reported for other
Ru complexes and also the clinically established Pt compoundsTable 3
pKa values of complexes 3a–e.
Compound pKa
3a 9.05 ± 0.02
3b 9.80 ± 0.03
3c 8.99 ± 0.01
3d 9.56 ± 0.01
3e 9.64 ± 0.02
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Fig. 6. Concentration–effect curves of 3a and 3c–e in CH1 ovarian carcinoma cells.
Fig. 4. Titration curve of 3c used to determine the pKa.
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n aqueous solutions) resulted in the formation of 50-GMP adducts
ithin seconds. After addition of an equimolar amount of the re-
ent, three new signals for the H8 of 50-GMP were observed in
e 1H NMR spectra between 7.7 and 7.9 ppm in a ratio of 1:1:2
ig. 5). The signals may be assigned to the four stereoisomers
rmed by the coordination of 50-GMP to the ruthenium center.
e change of the H8 signal in the 1H NMR spectrum from
15 ppm to approximately 7.80 ppm indicates coordination via
e N7 atom of the guanine [53]. The 31P NMR spectrum contains
peaks between 3.7 and 3.1 ppm in 1:1:2 ratio in agreement with
e 1H NMR spectra.
4. In vitro evaluation
The in vitro anticancer activity of 3a and 3c–e was determined
SW480 (colon carcinoma), CH1 (ovarian carcinoma) and A549
on-small cell lung carcinoma) human cancer cells using the col-
imetric MTT assay, yielding IC50 values mostly in the 105 M
nge (Table 2). Due to the low solubility of 3b it was not possible
determine its anticancer activity.
CH1 cells were found to be the most sensitive to all four ruthe-
um complexes, and in all cell lines 3c was the most active com-
und with an IC50 value of 24 lM in the ovarian cancer cell line
ig. 6). In general, it appears as the solubility in medium/DMSOfo
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th
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g. 5. 50-GMP binding of 3d studied by 1H NMR spectroscopy after addition of (a)
eq, (b) 1 eq, and (c) an excess of 50-GMP to a D2O solution of the Ru complex.
24a measure of lipophilicity determines the in vitro anticancer
tivity of the compounds (Table 2). Furthermore, the substituent
the aryl moiety of the ligand appears to inﬂuence the activity
the ruthenium complex in all tested cell lines: 3c and 3d with
eir electron withdrawing substituents exhibit a higher cytotoxic
tivity in CH1 cells than 3a. In contrast, electron-donating substit-
nts such as the methoxy groups in 3e do not signiﬁcantly inﬂu-
ce the activity in CH1 cells and are even disadvantageous in
480 and A549 cells. In comparison to the parent compound
-maltol, the compounds bearing substituents at the 2-position
e more cytotoxic, which may also be due to the increased lipo-
ilicity of the compounds (Table 2). However, in order to establish
ﬁnitive structure–activity relationships a higher number of com-
unds need to be studied.
Conclusions
Ruthenium complexes have been established as potential drug
ndidates for treatment of cancer. Herein, ruthenium(II)-p-cym-
e complexes with 2-substituted 3-hydroxypyran-4(1H)-one li-
nds have been evaluated for potential anticancer activity. The
mplexes hydrolyze rapidly in aqueous solutions, in a process
volving substitution of the chlorido ligand by an aqua ligand.
bstitution of the 2-position of the pyrone moiety results in in-
eased stability of the aqua complexes in aqueous solution in
mparison to Ru-maltol which affords dimeric species. The reac-
on of the Ru moiety toward 50-GMP is very fast, and binding oc-
rs selectively at the N7 of the guanine. Complexes 3a and 3c–e
hibit moderate cytotoxicity against SW480 and CH1 human tu-
or cell lines, and poor activity against A549 cells, suggesting a
rtain degree of selectivity. The aryl moiety seems to be relevant
r determining the in vitro activity of the compounds with elec-
on withdrawing substituents at the phenyl moiety decreasing
e IC50 value and electron donating groups having the opposite ef-
ct. There appears to be a correlation between the electronic effect
the substituents on the maltol-derived ligands, and the in vitro
tivity, but a larger library of compounds should be studied to
nﬁrm this hypothesis.
Experimental
1. Materials and methods
All solvents were dried and distilled prior to use. Ruthenium(III)
loride (Johnson Matthey), kojic acid (Fluka), benzaldehyde
luka), p-nitrobenzaldehyde (Aldrich), p-ﬂuorobenzaldehyde
luka), m-ﬂuorobenzaldehyde (Fluka), 3,4,5-trimethoxybenzalde-
de (Aldrich) and sodium methoxide (Aldrich) were purchased
d used without further puriﬁcation. Bis[dichlorido(g6-p-
mene)ruthenium(II)], 2-chloromethyl-5-hydroxypyran-4(1H)-
e (chlorokojic acid), and 5-hydroxy-2-methyl-pyran-4(1H)-one
926 W. Kandioller et al. / Journal of Organometallic Chemistry 694 (2009) 922–929(allomaltol, 1) were synthesized as described elsewhere [46,54].
Melting points were determined with a Büchi B-540 apparatus
and are uncorrected. Elemental analyses were carried out with a
Perkin Elmer 2400 CHN Elemental Analyzer at the Microanalytical
Laboratory of the University of Vienna. NMR spectra were recorded
at 25 C on a Bruker FT-NMR spectrometer Avance IIITM 500 MHz at
500.10 MHz (1H), 125.75 MHz (13C) and 202.44 MHz (31P) in
DMSO-d6, D2O or CDCl3. The 2D NMR spectra were measured in a
gradient-enhanced mode. An esquire3000 ion trap mass spectrome-
ter (Bruker Daltonics, Bremen, Germany), equipped with an
orthogonal ESI ion source, was used for MS measurements. The
solutions were introduced via ﬂow injection using a Cole-Parmer
74900 single-syringe infusion pump (Vernon Hills, IL). The ESI-
MS instrument was controlled by means of the ESQUIRECONTROL soft-
ware (version 5.2), and all data were processed using DATAANALYSIS
software (version 3.2) (both Bruker Daltonics). IR spectra were
measured in KBr matrix (4000–400 cm1) with a Bruker Vertex
70 FT-IR spectrometer.
Single crystals of 3b were grown from MeOH, and X-ray diffrac-
tion measurement was performed on a Bruker X8 APEXII CCD dif-
fractometer at 100 K. The single crystal was positioned at 40 mm
from the detector, and 2965 frames were measured, each for 3 s
over 1 scan width. The data were processed using the SAINT soft-
ware package [55]. Crystal data, data collection parameters, and
structure reﬁnement details are given in Table 4. The structure
was solved by direct methods and reﬁned by full-matrix least-
squares techniques. Non-hydrogen atoms were reﬁned with aniso-
tropic displacement parameters. H atoms were inserted at calcu-
lated positions and reﬁned with a riding model. The following
computer programs were used: structure solution, SHELXS-97 [56];
reﬁnement, SHELXL-97 [57]; molecular diagrams, ORTEP-3 [58]; com-
puter, Pentium IV; scattering factors [59].Table 4
Crystal data and details of data collection for 3b.
Chemical formula C23H24ClNO6Ru
M (g mol1) 546.95
Temperature (K) 100(2)
Crystal size (mm) 0.30  0.30  0.20
Crystal color, shape Orange, block
Crystal system Triclinic
Space group P1 (No 2)
a (Å) 7.4276(4)
b (Å) 12.5755(5)
c (Å) 12.6091(6)
a () 72.009(2)
b () 87.811(3)
c () 74.210(2)
V (Å3) 1076.55(9)
Z 2
Dc (g cm3) 1.687
l (cm1) 8.94
F(000) 556
h Range for data collection () 2.04–30.07
h range 10/10
k range 17/17
l range 17/17
Number of reﬂections used in reﬁnement 6280
Number of parameters 295
Rint 0.0354
R1
a 0.0212
wR2
b 0.0532
GOFc 1.007
Residuals (e Å3) 0.592, 0.490
a R1 =
P
||Fo|  |Fc||/
P
|Fo|.
b wR2 = {
P
[w(F2o  F2c)2]/w
P
(F2o)2]}1/2.
c GOF = {
P
[w(F2o  F2c)2] /(n  p)}1/2, where n is the number of reﬂections and p is
the total number of parameters reﬁned.
254.2. Synthesis
4.2.1. General procedure for the reaction of allomaltol with the
aldehydes
Allomaltol 1 (1 eq) and NaOH (1.1 eq) were dissolved in water
and stirred for 5 min. Afterwards, the aldehyde (1.1 eq) was added
dropwise to the reaction mixture. The solution was adjusted to pH
10.5 with 5 M NaOH solution and stirred at r.t. for 12 h. The reac-
tion mixture was acidiﬁed to pH 1 with conc. HCl and the resulting
precipitate was collected by ﬁltration. If no precipitation occurred,
the reaction mixture was extracted with CH2Cl2 (3  20 mL). The
combined organic layers were washed twice with saturated
NaHCO3 (30 mL) and water (30 mL), dried over Na2SO4, ﬁltered
and concentrated in vacuo. The crude product was puriﬁed by
recrystallization.
4.2.1.1. 2-(Hydroxy-phenyl-methyl)-3-hydroxy-6-methyl-pyran-4(1H)-
one (2a). The reaction was performed according to the general pro-
cedure using 1 (2.0 g, 15.8 mmol) and benzaldehyde (1.8 mL,
17.5 mmol). The crude product was recrystallized from 2-propanol
affording a white powder (3.3 g, 90%). M.p. 170–172 C (decomp.);
1H NMR (DMSO-d6) d: 2.18 (s, 3H, CH3), 5.99 (d, J = 4.5 Hz, 1H,
CHOHPh), 6.14 (d, J = 5.0 Hz, 1H, CHOHPh), 6.19 (s, 1H, CH), 7.27
(t, J = 7.5 Hz, 1H, Ph-H40), 7.35 (t, J = 7.5 Hz, 2H, Ph-H30/H50), 7.40
(d, J = 7.5 Hz, 2H, Ph-H20/H60); 13C NMR (DMSO-d6) d: 19.7 (CH3),
66.3 (CHPhOH), 111.6 (CH3C@CH), 126.4 (Ph-C20), 127.8 (Ph-C40),
128.7 (Ph-C30) 141.0 (CH3C@CH), 141.8 (Ph-C10), 151.0
(HOCHC@COH), 165.0 (CHOH), 174.3 (C@O); IR (KBr, cm1, se-
lected bands): 3323, 1654, 1607, 1562, 1256, 1209; Elemental
Anal. Calc. for C13H12O4  0.2H2O: C, 66.20; H, 5.30. Found: C,
66.24; H, 5.33%.
4.2.1.2. 2-[(4-Nitrophenyl)-hydroxy-methyl]-3-hydroxy-6-methyl-pyran-
4(1H)-one (2b). The reaction was performed according to the gen-
eral procedure using 1 (1.00 g, 7.9 mmol) and 4-nitrobenzaldehyde
(1.32 g, 8.7 mmol, in 2 mL dioxane). The crude product was puri-
ﬁed by recrystallization from 2-propanol affording yellow crystals
(1.41 g, 64%). M.p. >200 C decomp.; 1H NMR (DMSO-d6) d: 2.17 (s,
3H, CH3), 6.13 (s, 1H, CHOHAr), 6.21 (s, 1H, CH), 6.50 (brs, 1H, CHO-
HAr), 7.66 (d, J = 8.8 Hz, 2H, Ar-H20/H60), 8.23 (d, J = 8.6 Hz, 2H, Ar-
H30/H50), 9.34 (s, 1H, COH); 13C NMR (DMSO-d6) d: 20.1 (CH3), 66.2
(CHOHAr), 112.1 (CH3C@CH), 124.4 (Ar-C20/C60), 128.0 (Ar-C30/C50),
141.9 (CH3C@CH), 147.7 (Ar-C10), 149.8 (Ar-C40), 150.2
(HOCHC@COH), 165,6 (CHOH), 174,7 (C@O); IR (KBr, cm1, se-
lected bands): 3281, 1650, 1606, 1563, 1347, 1220; Elemental Anal.
Calc. for C13H11NO6  0.1H2O: C, 55.95; H, 4.04; N, 5.01. Found: C,
55.90; H, 3.98; N, 4.98%.
4.2.1.3. 2-[(4-Fluorophenyl)-hydroxy-methyl]-3-hydroxy-6-methyl-
pyran-4(1H)-one (2c). The reaction was performed according to
the general procedure using 1 (1.00 g, 8.0 mmol) and 4-ﬂuorobenz-
aldehyde (1.08 g, 8.8 mmol, in 1 mL dioxane), affording colorless
crystals (1.80 g, 91%). M.p. 158–160 C; MS (ESI)m/z 249 [MH];
1H NMR (DMSO-d6) d: 2.19 (s, 3H, CH3), 5.99 (s, 1H, CHOHAr), 6.20
(s, 1H, CH), 6.19 (brs, 1H, CHOHAr), 7.18 (t, J = 9.0 Hz, 2H, Ar-H30/
H50), 7.43 (dd, J = 9.0 Hz, J = 3.0 Hz, Ar-H20/H60), 9.10 (brs, 1H,
COH); 13C NMR (DMSO-d6) d: 19.7 (CH3), 66.7 (CHOHAr), 111.6
(CH3C@CH), 115.5 (J = 21.5 Hz, Ar-C30), 128.4 (J = 8.1 Hz, Ar-C20),
138.0 (J = 3.0 Hz, Ar-C10), 141.0 (CH3C@CH), 150.7 (HOCHC@COH),
161.9 (J = 242.0 Hz, Ar-C40), 165.1 (CHOH), 174.3 (C@O); IR (KBr,
cm1, selected bands): 3293, 1652, 1607, 1564, 1508, 1219; Ele-
mental Anal. Calc. for C13H11FO4  1=4H2O: C, 61.30; H, 4.55. Found:
C, 61.56; H, 4.39%.
4.2.1.4. 2-[(3-Fluorophenyl)-hydroxy-methyl]-3-hydroxy-6-methyl-
pyran-4(1H)-one (2d). The reaction was performed according to
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dehyde (0.54 g, 4.4 mmol, in 1 mL dioxane) affording colorless
ystals (0.85 g, 85%). M.p. 170–172 C; 1H NMR (DMSO-d6) d:
27 (s, 3H, CH3), 6.01 (s, 1H, CHOHAr), 6.20 (s, 1H, CH), 6.40
rs, CHOHAr) 7.10 (m, Ar-H40), 7.18–7.21 (m, 2H, Ar-H20/H60),
38 (q, J = 8.0 Hz, Ar-H50), 9.15 (brs, 1H, COH); 13C NMR (DMSO-
) d: 19.7 (CH3), 66.8 (CHOHAr), 111.7 (CH3C@CH) 113.0
= 22.1 Hz, Ar-C20), 114.6 (J = 21.3 Hz, Ar-C40), 122.4 (J = 3.0 Hz,
r-C60), 130.7 (J = 8.2 Hz, Ar-C50) 141.2 (CH3C@CH), 144.8
= 8.3 Hz, Ar-C10), 150.4 (HOCHC@COH), 162.0 (J = 242.1 Hz, Ar-
0), 165.1 (CHOH), 174.3 (C@O); IR (KBr, cm1, selected bands):
93, 1655, 1609, 1561, 1252, 1208; Elemental Anal. Calc. for
3H11FO4  1=4H2O: C, 61.30; H, 4.55. Found: C, 61.30; H, 4.45%.
2.1.5. 2-[(3,4,5-Trimethoxyphenyl)-hydroxy-methyl]-3-hydroxy-6-
ethyl-pyran-4(1H)-one (2e). The reaction was performed
cording to the general procedure using 1 (0.40 g, 3.2 mmol)
d 3,4,5-trimethoxybenzaldehyde (0.68 g, 3.5 mmol, in 5 mL
oxane) affording a pale yellow solid (0.78 g, 69%). M.p. 182–
4 C; 1H NMR (DMSO-d6) d: 2.22 (s, 3H, CH3), 3.64 (s, 3H, 40-
CH3), 3.76 (s, 6H, 30/50-OCH3), 5.95 (d, J = 5.2 Hz, 1H, CHOHAr),
15 (d, J = 5.2 Hz, 1H, CHOHAr), 6.20 (s, 1H, CH), 6.71 (s, 2H, Ar-
30/H50), 9.05 (brs, 1H, COH); 13C NMR (DMSO-d6) d: 19.7 (CH3),
.3 (30/50-OCH3), 60.5 (40-OCH3) 66.4 (CHOHAr), 103.7 (Ar-C20/
0), 111.6 (CH3C@CH), 137.2 (Ar-C10), 137.4 (Ar-C40), 140.0
H3C@CH), 150.8 (HOCHC@COH), 153.2 (Ar-C30/C50), 165.0
HOH), 174.3 (C@O); IR (KBr, cm1, selected bands): 3416, 3293,
46, 1600, 1558, 1226, 1126; Elemental Anal. Calc. for
6H18O7  1=4H2O: C, 58.80; H, 5.71. Found: C, 58.84; H, 5.42%.
2.2. General procedure for the synthesis of the Ru(II) complexes
The maltol-derived ligand (0.73 mmol) and sodium methoxide
3 mg, 0.80 mmol) were dissolved in methanol (15 mL) and stir-
d for 5 min under inert atmosphere to give a clear solution. After-
ards, bis[dichlorido(g6-p-cymene)ruthenium(II)] (200 mg,
33 mmol) was dissolved in CH2Cl2 (5 mL) and added dropwise
the reaction mixture which was stirred for further 5 (for 3a)
18 h. The reaction mixture was concentrated in vacuo, and the
sidue was extracted with CH2Cl2 (3  15 mL). The combined or-
nic layers were ﬁltered, and the solvent was removed. The crude
oduct was puriﬁed by recrystallization or precipitation.
2.2.1. Chlorido[2-(hydroxy-phenyl-methyl)-6-methyl-3-(oxo-jO)-
ran-4(1H)-onato-jO4](g6-p-cymene)ruthenium(II) (3a). The
action was performed according to the general complexation
otocol using 2a (168 mg, 0.73 mmol). The crude product was
crystallized from EtOAc/n-hexane affording a red crystalline so-
(240 mg, 73%). M.p. 160–165 C decomp.; MS (ESI+) m/z 391
Cl]+; 1H NMR (CDCl3) d: 1.30–1.38 (m, 6H, CH3), 2.19 (s, 3H,
3,pyr), 2.33 (s, 3H, CH3,cym), 2.93 (m, 1H, CH(CH3)2,cym), 5.28–
33 (m, 2H, Arcym-H3/H5), 5.52–5.57 (m, 2H, Arcym-H2/H6), 5.81
, 1H, CHOHPh), 5.86 (s, 1H, CHOHPh), 6.27 (s, 1H, CH), 7.30–
50 (m, 5H, Ph); 13C NMR (CDCl3) d: 18.6 (CH3), 19.8 (CH3cym),
.3 (CH3,cym), 31.2 (CH(CH3)2), 72.9 (CHOHPh), 78.2 (Arcym-C3/
), 80.2 (Arcym-C2/C6), 95.8 (Arcym-C4), 99.5 (Arcym-C1), 109.4
H), 127.1 (Ph-C2), 128.0 (Ph), 128.5 (Ph), 141.5 (CH3C@CH),
2.9 (Ph-C1), 155.1 (HOCHC@COH), 164.2 (CHOH), 185.0 (C@O);
(KBr, cm1, selected bands): 3394, 1604, 1561, 1503, 1476,
59, 1206; Elemental Anal. Calc. for C23H25ClO4Ru: C, 55.03; H,
02. Found: C, 54.73; H, 5.02%.
2.2.2. Chlorido{2-[(4-nitrophenyl)-hydroxy-methyl)]-6-methyl-
(oxo-jO)-pyran-4-(1H)-onato-jO4}(g6-p-cymene)ruthenium(II)
b). The reaction was performed according to the general com-
exation protocol using 2b (197 mg, 0.73 mmol). The crude prod-
t was recrystallized from EtOAc/diethyl ether/n-hexane26fording an orange powder (250 mg, 70%). M.p. 180–185 C de-
mp.; MS (ESI+) m/z 512 [MCl]+; 1H NMR (CDCl3) d: 1.31–1.40
, 6H, CH3,cym), 2.19 (s, 3H, CH3,pyr), 2.34 (s, 3H, CH3,cym), 2.92
, 1H, CH(CH3)2), 5.29–5.35 (m, 2H, Arcym-H3/H5); 5.51–5.58
, 2H, Arcym-H2/H6), 5.93 (bs, 1H, CHOHAr), 5.99 (bs, 1H, CHO-
Ar), 6.30 (s, 1H, CH), 7.67–7.70 (m, 2H, Arcym-H2/H6), 8.20–8.25
, 2H, Arcym-H30/H50); 13C NMR (CDCl3) d: 18.6 (CH3,pyr),
.9 (CH3,cym), 22.5 (CH3,cym), 31.2 (CH(CH3)2), 71.7 (CHOHAr),
.0 (Arcym-C3/C5), 80.3 (Arcym-C2/C6), 95.7 (Arcym-C4), 99.4
rcym-C1), 109.5 (CH), 123.6 (Ar-C2/C6), 127.5 (Ar-C3/C5), 148.0
r-C1), 148.6 (Ar-C4), 151.0 (CH3C@CH), 155.5 (HOCHC@COH),
4.7 (CHOH), 185.2 (C@O); IR (KBr, cm1, selected bands): 3342,
03, 1564, 1513, 1477, 1256, 1205; Elemental Anal. Calc. for
3H24ClNO6Ru: C, 50.51; H, 4.42; N, 2.56. Found: C, 50.35; H,
39; N, 2.51%.
2.2.3. Chlorido{2-[(4-ﬂuorophenyl)-hydroxy-methyl)]-6-methyl-3-
xo-jO)-pyran-4-(1H)-onato-jO4}(g6-p-cymene)ruthenium(II)
c). The reaction was performed according to the general com-
exation protocol using 2c (183 mg, 0.73 mmol). The crude prod-
t was recrystallized from EtOAc/diethyl ether/n-hexane,
fording an orange powder (240 mg, 71%). M.p. 90–95 C decomp.;
S (ESI+) m/z 485 [MCl]+; 1H NMR (CDCl3) d: 1.30–1.38 (m, 6H,
3,cym), 2.20 (s, 3H, CH3,pyr), 2.33 (s, 3H,CH3,cym), 2.92 (m, 1H,
(CH3)2), 5.28–5.33 (m, 2H, Arcym-H3/H5), 5.53–5.57 (m, 2H,
rcym-H2/H6), 5.76 (bs, 1H, CHOHAr), 5.89 (bs, 1H, CHOHAr), 6.28
, 1H, CH), 6.99–7.07 (m, 2H, Ar-H3/H5), 7.46–7.48 (m, 2H,
r-H2/H6); 13C NMR (CDCl3) d: 18.6 (CH3,pyr), 19.8 (CH3,cym), 22.4
H3,cym), 31.2 (CH(CH3)2), 72.2 (CHOHAr), 78.1 (Arcym-C3/C5),
.2 (Arcym-C2/C6), 95.7 (Arcym-C4), 99.3 (Arcym-C1), 109.4 (CH),
5.3 (J = 22.3 Hz, Ar-C3/C5), 128.5 (J = 8.0 Hz, Ar-C2/C6), 137.3
= 4.1 Hz, Ar-C1), 152.2 (CH3C@CH), 155.2 (HOCHC@COH), 162.5
= 245.7 Hz, Ar-C4), 164.0 (CHOH), 185.0 (C@O); IR (KBr, cm1, se-
cted bands): 3387, 1603, 1563, 1507, 1477, 1219; Elemental
nal. Calc. for C23H24ClFO4Ru: C, 53.13; H, 4.65. Found: C, 52.86;
, 4.62%.
2.2.4. Chlorido{2-[(3-ﬂuorophenyl)-hydroxy-methyl)]-6-methyl-
(oxo-jO)-pyran-4-(1H)-onato-jO4}(g6-p-cymene)ruthenium(II)
d). The reaction was performed according to the general com-
exation protocol using 2d (183 mg, 0.73 mmol). The crude prod-
t was recrystallized from EtOAc/diethyl ether/n-hexane
fording an orange powder (250 mg, 73%). M.p. 160–165 C de-
mp.; MS (ESI+) m/z 485 [MCl]+; 1H NMR (CDCl3) d: 1.30–1.38
, 6H, CH3,cym), 2.20 (s, 3H, CH3,pyr), 2.33 (s, 3H, CH3,cym), 2.92
, 1H, CH(CH3)2), 5.30 (m, 2H, Arcym-H3/H5), 5.54 (m, 2H, Ar-
m-H2/H6), 5.83 (brs, 1H, CHOHAr), 6.01 (brs, 1H, CHOHAr), 6.28
, 1H, CH), 6.99 (m, 1H, Ar-H4), 7.22–7.33 (m, 3H, Ar-H2/H5/
6); 13C NMR (CDCl3) d: 18.6 (CH3,pyr), 19.8 (CH3,cym), 22.2
H3,cym), 31.2 (CH(CH3)2), 72.4 (CHOHAr), 78.1 (Arcym-C3/C5),
.2 (Arcym-C2/C6), 95.7 (Arcym-C4), 99.4 (Arcym-C1), 109.4 (CH),
3.9 (J = 22.3 Hz, Ar-C2), 114.7 (J = 22.2 Hz, Ar-C4), 122.3
= 3.0 Hz, Ar-C6), 129.9 (J = 7.4 Hz, Ar-C5), 144.0 (J = 7.2 Hz, Ar-
), 152.1 (CH3C@CH), 155.2 (HOCHC@COH), 162.8 (J = 262.4 Hz,
r-C3), 164.2 (CHOH), 185.0 (C@O); IR (KBr, cm1, selected bands):
96, 1604, 1562, 1504, 1476, 1250, 1203; Elemental Anal. Calc. for
3H24ClFO4Ru: C, 53.13; H, 4.65. Found: C, 53.11; H, 4.65%.
2.2.5. Chlorido{2-[(3,4,5-trimethoxyphenyl)-hydroxy-methyl)]-
methyl-3-(oxo-jO)-pyran-4-(1H)-onato-jO4}(g6-p-cymene)ruthe-
um(II) (3e). The reaction was performed according to the general
mplexation protocol using 2e (234 mg, 0.73 mmol. The crude
oduct was recrystallized from EtOAc/n-hexane, affording an or-
ge powder (200 mg, 54%). M.p. 160–165 C decomp.; MS (ESI+)
/z 557 [MCl]+; 1H NMR (CDCl3) d: 1.37–1.39 (m, 6H, CH3,cym),
22 (s, 3H, CH3,pyr), 2.32 (s, 3H, CH3,cym), 2.93 (m, 1H, CH(CH3)2),
928 W. Kandioller et al. / Journal of Organometallic Chemistry 694 (2009) 922–9293.82 (s, 3H, 40-OCH3), 3.89 (s, 6H, 30/50-OCH3) 5.29–5.31 (m, 2H,
Arcym-H3/H5), 5.89 (m, 1H, CHOHAr), 6.30 (s, 1H, CH), 6.72 (s,
2H, Ar-H2/H6); 13C NMR (CDCl3) d: 18.6 (CH3,pyr), 19.8 (CH3,cym),
22.3 (CH3,cym), 31.2 (CH(CH3)2), 56.4 (30/50-OCH3), 60.7 (40-OCH3),
71.8 (CHOHAr), 77.8 (Arcym-C3/C5), 80.5 (Arcym-C2/C6), 95.4
(Arcym-C4), 99.0 (Arcym-C1), 104.3 (Ar-C2/C6), 109.4 (CH), 136.8
(Ar-C1), 137.8 (Ar-C4), 152.8 (CH3C@CH), 153.3 (Ar-C3/C5), 155.2
(HOCHC@COH), 164.1 (CHOH), 185.0 (C@O); IR (KBr, cm1,
selected bands): 3383, 1603, 1567, 1510, 1473, 1417, 1326, 1238,
1124; Elemental Anal. Calc. for C26H31ClO7Ru: C, 52.75; H, 5.28.
Found: C, 52.80; H, 5.32%.
4.3. GMP binding
Complexes 3a–e (1–2 mg/mL)were dissolved in D2O containing
5% DMSO-d6. The solution was titrated with a 50-GMP solution
(10 mg/mL) in 50 lL increments, and the reaction was monitored
by 1H and 31P NMR spectroscopy until unreacted 50-GMP was
detected.
4.4. pKa determination
Complexes 3a–ewere dissolved in D2O containing 5% DMSO-d6.
The pH value was measured directly in the NMR tubes with an Eco
Scan pH6 pH meter equipped with a glass-micro combination pH
electrode (Orion 9826BN) and calibrated with standard buffer solu-
tions of pH 4.00, 7.00 and 10.00. The pH titration was performed by
addition of NaOD (0.4–0.0004% in D2O) and DNO3 (0.4–0.0004% in
D2O). The observed shifts of the Arcym-H2/H6 protons of the arene
ring in the 1H NMR spectra were plotted against the pH value, and
the obtained curves were ﬁtted using the Henderson-Hasselbalch
equation with Excel software (Microsoft Ofﬁce Excel 2003, SP3,
Microsoft Corporation). The experimentally obtained pKa values
were corrected with Eq. (1) [60], in order to convert the pKa in
D2O to corresponding pKa values in aqueous solutions.
pKa ¼ 0:929pKa þ 0:42 ð1Þ4.5. Cytotoxicity in cancer cell lines
4.5.1. Cell lines and conditions
CH1 cells originate from an ascites sample of a patient with a
papillary cystadenocarcinoma of the ovary and were a generous
gift from Lloyd R. Kelland, CRC Centre for Cancer Therapeutics,
Institute of Cancer Research, Sutton, UK. SW480 (adenocarcinoma
of the colon) and A549 (non-small cell lung cancer) cells were
kindly provided by Brigitte Marian (Institute of Cancer Research,
Department of Medicine I, Medical University of Vienna, Austria).
All cell culture reagents were obtained from Sigma–Aldrich Aus-
tria. Cells were grown in 75 cm2 culture ﬂasks (Iwaki) as adherent
monolayer cultures in Minimal Essential Medium (MEM) supple-
mented with 10% heat-inactivated fetal calf serum, 1 mM sodium
pyruvate, 4 mM L-glutamine and 1% non-essential amino acids
(100). Cultures were maintained at 37 C in a humidiﬁed atmo-
sphere containing 5% CO2.
4.5.2. MTT assay conditions
Cytotoxicity was determined by the colorimetric MTT (3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, pur-
chased from Fluka) microculture assay. For this purpose, cells were
harvested from culture ﬂasks by trypsinization and seeded into 96-
well microculture plates (Iwaki). Cell densities of 1.5  103 cells/
well (CH1), 2.5  103 cells/well (SW480) and 4  103 cells/well
(A549) were chosen in order to ensure exponential growth
throughout drug exposure. Cells were allowed to settle in drug-free
complete culture medium for 24 h. Stocks of the test compounds in27DMSO were diluted in complete culture medium such that the
maximum DMSO content did not exceed 1% (this procedure
yielded opaque but colloidal solutions from which no precipitates
could be separated by centrifugation). These dilutions were added
in 200 lL aliquots to the microcultures after removal of the pre-
incubation medium, and cells were exposed to the test compounds
for 96 h. At the end of exposure, all media were replaced by 100 lL/
well RPMI1640 culture medium (supplemented with 10% heat-
inactivated fetal bovine serum and 4 mM L-glutamine) plus
20 lL/well MTT solution in phosphate-buffered saline (5 mg/mL).
After incubation for 4 h, the supernatants were removed, and the
formazan crystals formed by vital cells were dissolved in 150 lL
DMSO per well. Optical densities at 550 nm were measured with
a microplate reader (Tecan Spectra Classic), using a reference
wavelength of 690 nm. The quantity of vital cells was expressed
in terms of T/C values by comparison to untreated control micro-
cultures, and 50% inhibitory concentrations (IC50) were calculated
from concentration–effect curves by interpolation. Evaluation is
based on means from three independent experiments, each com-
prising six replicates per concentration level.
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Ru(II)-arene complexes with pyrone-derived ligands are rendered active against cancer cells 
by replacement of the coordinated O,O donor with an S,O donor. The different stabilities of 
these systems may explain the observed influence of the donor atoms on the anticancer activ-
ity in vitro. 
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ABSTRACT.  
Ru(II)-arene complexes with maltolato ligands are inactive in tumor cell lines, probably due to 
formation of dimeric species. Switching from pyrones to thiopyrones renders such compounds active 
against cancer cells. These complexes are significantly more stable in aqueous solution, as shown by 
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formation. The different stabilities of these systems may explain the observed influence of the donor 
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Metal complexes are playing an important role in the treatment of cancer, and many promising 
compounds have been developed in recent years.1-4 Ruthenium complexes have been shown to be 
among the most promising candidates for new metal-based anticancer drugs. Two of them, KP1019 and 
NAMI-A, are currently undergoing clinical trials.2,5 Their low general toxicity might be explained by 
their modes of action, including protein binding and activation by reduction.5-7 
More recently, bioorganometallic chemistry has emerged as a new source of anticancer metallodrugs, 
with titanocene dichloride being the prototype agent of this compound class.4,8,9 Furthermore, 
organometallic Ru(II) compounds, that are stabilized in their +2 oxidation state by coordination of an 
arene ligand, have been investigated for their anticancer properties. These piano-stool complexes have 
been pioneered by the Dyson and Sadler groups,10,11 who developed compounds with pta (1,3,5-triaza-7-
phoshatricyclo[3.3.1.1]decane] and en (ethylenediamine) ligands, respectively.10 For the [(η6-
arene)Ru(II)(X)(Y)] complexes, DNA base selectivity strongly depends on the character of the chelating 
ligand Y – exchange of the neutral ethylenediamine by anionic acetylacetonate shifts the affinity from 
guanine to adenine.12 Besides en and pta complexes, maltol-derived mono- and polynuclear ruthenium 
and osmium complexes have been developed.13-15 The linking of two pyridone moieties opened up new 
possibilities for tuning the in vitro anticancer activity and lipophilicity, and compounds with interduplex 
cross-linking capacity were obtained.14,16-18 In the case of the mononuclear Ru(II) complexes, an 
increase in cytotoxic activity was achieved by derivatization of the pyrone ring with lipophilic aromatic 
substitutents.13 
In order to study the Ru–ligand interaction and its effect on the in vitro anticancer activity, Ru(II)–
cymene complexes (Scheme 1) with pyrones and their corresponding, more lipophilic thiopyrones as 
chelating agents were prepared.15,19 Such (thio)pyrone systems found already application in medicinal 
chemistry.20,21 The Ru(II)–cymene complexes were obtained in good yields (64–85%) by deprotonation 
of the ligand with sodium methoxide and reaction with bis[dichlorido(η6-p-cymene)ruthenium(II)]. The 
reaction was performed with a slight excess of ligand to facilitate the purification. All complexes have 
been fully characterized by 1D and 2D NMR spectroscopy, mass spectrometry and elemental analysis. 
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Scheme 1. Synthesis of the complexes 2a–d. 
 
Single crystals of 2b were obtained from ethyl acetate, and the molecular structure was determined by 
X-ray diffraction analysis. The ruthenium center was found to adopt piano-stool configuration (Figure 1; 
Supporting Information). Due to the larger sulfur atom in 2b as compared to the oxygen in maltol-
derived ligands, the Ru–S bond (2.3730(3) Å) is significantly longer than the Ru–O bond 
(2.0808(10) Å). This leads to a strong distortion of the 5-membered chelate ring of the complex. The 
length of the Ru–Cl bond in 2b (2.4331(4) Å) is comparable to the corresponding bond lengths of 
pyrone and pyridone Ru(II)–arene complexes.14,15 
 
Figure 1. ORTEP plot of the molecular structure of 2b. 
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The antiproliferative activities of 2a–d were investigated in the human tumor cell lines SW480 (colon 
carcinoma) and CH1 (ovarian carcinoma) by using the colorimetric MTT assay (Figure 2). The IC50 
values are presented in Table 1. As reported earlier,14 the maltol complex 2a shows limited cytotoxic 
activity, and the allomaltol derivative 2c has IC50 values > 200 µM. In contrast, the thiopyrone 
complexes 2b and 2d are at least by an order of magnitude (in IC50) more active than their pyrone 
analogues. For complexes 2b and 2d, an inverted sensitivity of SW480 cells and CH1 cells was 
observed, which contrasts with a broad spectrum of other compounds, but parallels that observed with 
Ru(II)–arene complexes containing an 8-quinolinolato ligand.22 The substitution pattern influences the 
activity, as inferred from the 2.7–3.9 times higher activity of 2b as compared to 2d. These compounds 
are less cytotoxic than other ruthenium complexes,23 but still in a reasonable range of activity in vitro 
when compared to other Ru–arene species.22 However, the in vitro activity is only a first indication for 
potential activity and the results need to be reproduced in vivo. 
 
Table 1. Antiproliferative activity, ∆G of hydrolysis and bond energies (kcal/mol) of 2a–d (2’a–d). 
  2a 2b 2c 2d 
CH1 81 ± 14 13 ± 4 239 ± 22 35 ± 8 IC50 [µM] 
SW480 159 ± 41 5.1 ± 0.5 359 ± 119 20 ± 7 
  2’a 2’b 2’c 2’d 
∆Ghydr 4.2 3.3 4.9 3.6 
E(Ru–Cl) 10.6 7.1 11.1 7.9 
E(Ru–O/S)(O/S=C) 26.8 34.6 26.4 34.4 
E(Ru–O)(O–C) 36.9 35.7 36.6 36.2 
 
The in vitro inactivity of the maltolato complexes has been attributed to the formation of dimers in 
aqueous solution.13 Accordingly, hydrolysis/stability in water were investigated by NMR spectroscopy 
in D2O or 10% DMSO-d6/D2O solutions for the maltol and thiomaltol compounds, respectively. The 
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complexes 2a–d hydrolyze within seconds to charged complexes by exchange of the chlorido ligand 
with a water molecule (Figure 2). No coordination of DMSO-d6 was observed, and identical NMR 
spectra were obtained by activation of 2a and 2c with an equimolar amount of AgNO3, which confirms 
the obtained results. Similarly to 2a,13 the formation of a dimeric species was observed for 2c (Figure 2, 
top left), as demonstrated by ESI-MS with a sample of 25 µM; this concentration was chosen in order to 
obtain a mass spectrum containing both the intact complex and the dimeric species. The amount of 
formed side product depends on the concentration, time and pH value of the solution and its formation 
can be prevented by addition of an equimolar amount of imidazole, as also demonstrated by means of 
ESI-MS (Figure 2, top right). 
Hydrolysis of 2b and 2d in 10% DMSO-d6/D2O results in the rapid formation of aqua species, which 
are stable for more than 24 h, and in contrast to the maltolato complexes, no dimers have been observed. 
To explain these observations, theoretical DFT calculations (B3LYP, Gaussian 03 program package,24 
see Supporting Information for computational details) of the metal–ligand bond energies have been 
performed. They reveal that the Ru–S(S=C) bond energies in the model complexes 2'b and 2'd (bearing 
benzene instead of cymene in 2b and 2d) are by 7.8–8.0 kcal/mol higher than the Ru–O(O=C) bond 
energies in 2'a and 2'c, respectively. In contrast, the Ru–O(O–C) bond energies in thiopyrone complexes 
are lower than those in pyrone species but only by 0.4–1.2 kcal/mol. The stronger binding of thiopyrones 
to Ru as compared to pyrones explains why thiopyrone complexes are stable in aqueous solution while 
pyrone complexes undergo decomposition with release of the ligands 1a and 1c. 
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Figure 2. The hydrolysis of Ru-(thio)pyronato complexes (X = O or S) yields in the case of the pyrone 
ligands the dimeric [Ru2(cym)2(OH)3]+ species (as demonstrated by ESI-MS; top left). When the aqua 
complexes 3a and 3c are reacted with imidazole, no dimerization was observed (top right), as is the case 
for the thiopyrone compounds 3b and 3d, which show significant cytotoxic activity in human cancer cell 
lines (bottom right).  
 
Theoretical calculations of 2'a–d and 3'a–d show that ∆G values for the substitution of chloride with 
H2O are only slightly positive (3.3–4.9 kcal/mol). Taking into account the large excess of water, 
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complexes 3a–d are the predominant species in aqueous solutions. Lower Ru–Cl bond energies in 2'b 
and 2'd as compared to 2'a and 2'c, respectively, correlate with ∆G values of hydrolysis (Table 1). 
Summarizing, the modification of the first ligand sphere and therewith of the stability of the 
complexes influences significantly the in vitro anticancer activity. Pyrone and thiopyrone compounds 
behave quite differently in water (dimer formation) and when reacted with biological molecules. These 
features have important implications for the mode of action of the compounds and result in considerably 
active thiopyrone vs. minimally active pyrone complexes. Furthermore, complexes 2b and 2d are 
slightly more active in SW480 cells, though CH1 cells are in our experience more chemosensitive to the 
vast majority of metal-based and other tumor-inhibiting compounds tested so far. 
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Scheme 1. Synthesis of the complexes 2a–d. 
Figure 1. ORTEP plot of the molecular structure of 2b. 
Figure 2. Hydrolysis scheme of Ru-(thio)pyronato complexes; X = O or S. 
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Table 1. Antiproliferative activity, ∆G of hydrolysis and bond energies (kcal/mol) of 2a–d (2’a–d). 
  2a 2b 2c 2d 
CH1 > 100 13 ± 4 239 ± 22 34 ± 8 IC50 [µM] 
SW480 > 100 5.1 ± 0.5 359 ± 119 20 ± 7 
  2’a 2’b 2’c 2’d 
∆Ghydr 4.2 3.3 4.9 3.6 
E(Ru–Cl) 10.6 7.1 11.1 7.9 
E(Ru–O/S)(O/S=C) 26.8 34.6 26.4 34.4 
E(Ru–O)(O–C) 36.9 35.7 36.6 36.2 
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1. General Procedure for the Synthesis of the Complexes 
 
The maltol-derived ligand (1 eq) and sodium methoxide (1.1 eq) were dissolved in methanol and 
stirred for 5 min under inert atmosphere to give a clear solution. Afterwards, bis[dichlorido(η6-p-
cymene)ruthenium(II)] (0.9 eq) was dissolved in CH2Cl2 and added dropwise to the reaction 
mixture, which was stirred for further 4 h. The red solution was concentrated in vacuo and the 
residue was extracted with CH2Cl2.The combined organic layers were filtered and the solvent was 
removed. The crude product was purified by precipitation. 
 
 
2. Characterization 
 
2.1. Elemental Analysis Data 
 
C [%] H [%] N [%] S [%] 
Compound 
calc. found calc. found calc. found calc. found 
2a 
C16H19ClO3Ru 
48.55 48.45 4.84 4.63 0.00 <0.05 0.00 <0.05 
2b 
C16H19ClO2RuS 
46.65 47.03 4.65 4.57 0.00 <0.05 7.78 7.67 
2c 
C16H19ClO3Ru 
48.55 48.12 4.84 4.79 0.00 <0.05 0.00 <0.05 
2d 
C16H19ClO2RuS 
46.65 46.24 4.65 4.61 0.00 <0.05 7.78 8.04 
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2.2. X-Ray Diffraction Data 
 
Chemical formula C16H19ClO2RuS 
M (g mol-1) 411.89 
Temperature (K) 100(2)  
Crystal size (mm) 0.30 × 0.22 × 0.15 
Crystal color, shape red, block 
Crystal system monoclinic 
Space group P21/n 
a (Å) 8.3191(2) 
b (Å) 14.8407(4) 
c (Å) 12.9576(3) 
ß (°) 99.769(1) 
V (Å3) 1576.56(7) 
Z 4 
Dc (g cm-3) 1.735 
µ (cm-1) 12.97 
F(000) 932 
θ range for data collection (°) 2.72–30.09 
h range -11/11 
k range -20/20 
l range -18/18 
No. refls. used in refinement 4622 
No. parameters 192 
Rint 0.0287 
R1a 0.0175 
wR2b 0.0432 
GOFc 1.047 
residuals, e- Å-3 0.438, -0.408 
a
 R1 = Σ||Fo| - |Fc||/Σ|Fo|. 
b wR2 = {Σ[w(Fo2 – Fc2)2]/wΣ(Fo2)2]}1/2. 
c GOF = {Σ[w(Fo2 – Fc2)2] /(n – p)}1/2, where n is the number of reflections and p is the total 
number of parameters refined. 
46
S5 
 
2.3. Mass Spectrometric Characterization of the Dimeric Hydrolysis Product 
 
The mass spectrometry data on the dimer formation was collected from samples prepared in H2O 
(2.5 mM, 250 µM, 25 µM and 2.5 µM). The samples were introduced into the MS by flow 
injection and the spectra were recorded in the positive ion mode. 
The abundance of the peak assigned to the dimeric [Ru2(cym)2(OH)3]+ ion was dependent on the 
concentration, temperature and pH. The lower the concentration, the more abundant was the peak 
in the MS. However, at 2.5 µM the signal to noise ratio limited the analysis of the sample and a 
concentration of 25 µM was identified as ideal for the experiment. In addition, the higher the pH, 
the quicker the dimer was formed, and also longer incubation time yielded higher amounts of the 
dimer (an optimum of 18 h was found). 
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3.  Computational Details 
 
The full geometry optimization of all structures has been carried out at the DFT level of theory 
using Becke’s three-parameter hybrid exchange functionalS1 in combination with the gradient-
corrected correlation functional of Lee, Yang and ParrS2 (B3LYP) with the help of the Gaussian-
03S3 program package. Symmetry operations were not applied for all structures. The geometry 
optimization was carried out using a quasi-relativistic Stuttgart pseudopotential described 28 core 
electrons and the appropriate contracted basis set (8s7p6d)/[6s5p3d]S4 for the ruthenium atom and 
the 6-31G(d) basis set for other atoms. Then single-point calculations were performed in the basis 
of the found equilibrium geometries using the 6-31+G(d,p) basis set for non-metal atoms. The 
experimental X-ray structure of 2b (this work) was chosen as the starting geometry for the 
optimizations. The Hessian matrix was calculated analytically for all optimized structures in order 
to prove the location of correct minima (no “imaginary” frequencies), and to estimate 
thermodynamic parameters, the latter were calculated at 25 °C. 
Solvent effects were taken into account at the single-point calculations based on the gas-phase 
equilibrium geometries at the CPCM-B3LYP/6-31+G(d,p)//gas-B3LYP/6-31G(d) level of theory 
using the polarizable continuum model in the CPCM versionS5,S6 with H2O as a solvent and UAKS 
atomic radii. The Gibbs free energies in solution (Gs) were estimated by addition of the solvation 
energy δGsolv to gas-phase Gibbs free energies (Gg). 
The Ru–O(O/S=C) bond energies have been calculated using the expression: 
 
Ebs(Ru–O/S(O/S=C)) = Es(R2'a–d) – Es(2'a–d) 
 
where R2'a–d corresponds to complexes 2'a–d but in which the organic ligand was rotated around 
the C(2)–O(1) bond by 50° so that the Ru–O/S(O/S=C) bond becomes broken while other bond 
lengths and angles remain the same (except the angle RuO(4)C(3)). The torsion angle 
RuO(1)C(2)C(3) is –11.29° in 2'a, –61.29° in R2'a, –11.71° in 2'b, –61.71° in R2'b, –10.67° in 
2'c, –60.67° in R2'c, –10.47° in 2'd and –60.47° in R2'd. 
The Ru–O(O–C) bond energies have been calculated using the expression: 
 
Ebs(Ru–O(O–C)) = Es(R'2'a–d) – Es(2'a–d) 
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where R'2'a–d corresponds to complexes 2'a–d but in which the organic ligand was rotated 
around the C(3)O(4) bond by 50° so that the Ru–O(O–C) bond becomes broken while other bond 
lengths and angles remain the same (except the angle RuO(1)C(2)). The torsion angle 
RuO(4)C(3)C(2) is 7.43° in 2'a, 57.43° in R'2'a, 5.06° in 2'b, 55.06° in R'2'b, 7.62° in 2'c, 57.62° 
in R'2'c, 4.65° in 2'd and 54.65° in R'2'd. It is necessary to mention that in R2'a–d and R'2'a–d 
the distances between any atom of the organic ligand (except the donor one) and the Ru atoms are 
not smaller than 2.7 Å. Thus, there are no new steric interactions in R2'a–d and R'2'a–d between 
the organic ligand and the metal, which might affect the bond energies calculated by this method. 
The equilibrium geometries and the main calculated bond lengths of 2’b are in perfect agreement 
with the experimental X-ray structural data for 2b (this work). The maximum deviation of the 
theoretical and experimental parameters is 0.03 Å for the Ru–S bond, whereas the difference for 
the other bonds does not exceed 0.018 Å, often falling within the 3σ interval of the X-ray data. 
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Figure S1. Equilibrium structures of the calculated pyrone complexes with numbering of selected 
atoms. Structures of the thiopyrone species are similar. 
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Table S1. Total energies, enthalpies and Gibbs free energies for the gas-phase and H2O solution 
(Hartree) of the calculated structures. 
 
Eg(6-31G*) Eg(6-31+G**) Es Hg Gg Gs 
H2O –76.408953 –76.433933 –76.445244 –76.384013 –76.406114 –76.417425 
H3O+ –76.689084 –76.707574 –76.880432 –76.650930 –76.673921 –76.846779 
Cl– –460.252233 –460.274726 –460.388702 –460.249873 –460.267256 –460.381232 
2’a –1244.752725 –1244.785467 –1244.808913 –1244.528795 –1244.589480 –1244.612926 
3’a –860.753112 –860.793688 –860.870726 –860.503495 –860.565452 –860.642490 
6’a –860.334699 –860.375987 –860.401011 –860.099002 –860.160042 –860.185066 
2’b –1567.725128 –1567.756490 –1567.779352 –1567.503125 –1567.566512 –1567.589374 
3’b –1183.730680 –1183.769920 –1183.844267 –1183.482906 –1183.545901 –1183.620248 
6’b –1183.306404 –1183.346214 –1183.370216 –1183.072593 –1183.135279 –1183.159281 
2’c –1244.752547 –1244.785001 –1244.810377 –1244.528703 –1244.589490 –1244.614866 
3’c –860.753388 –860.793873 –860.871775 –860.503809 –860.565338 –860.643240 
6’c –860.334962 –860.375987 –860.402292 –860.099323 –860.159878 –860.186183 
2’d –1567.724717 –1567.755941 –1567.780854 –1567.502724 –1567.565314 –1567.590227 
3’d –1183.730836 –1183.769955 –1183.844913 –1183.483090 –1183.545807 –1183.620765 
6’d –1183.305917 –1183.345628 –1183.371532 –1183.072164 –1183.134632 –1183.160536 
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Table S2. Cartesian coordinates (Å) of the calculated equilibrium structures of the complexes. 
 
2’a 
Ru 1.263322 0.694785 -0.519390 
Cl 1.374085 -0.465312 -2.629825 
O -0.416880 -4.063596 0.661424 
O 1.691882 -1.147331 0.357558 
O -0.675472 -0.156716 -0.366232 
C 0.514582 2.612129 0.215428 
H -0.525502 2.801025 0.462731 
C 1.386707 2.093188 1.216396 
H 1.025632 1.911221 2.222159 
C 0.960126 2.817668 -1.124385 
C 0.654991 -1.955006 0.333449 
C 3.150286 1.839025 -0.511609 
H 4.116683 1.451678 -0.811736 
C 2.270846 2.404604 -1.479495 
H 2.567746 2.416597 -2.522253 
C 0.716202 -3.293023 0.665089 
C -0.627787 -1.390052 -0.036275 
C 1.945719 -4.042041 1.044665 
C 2.686740 1.666359 0.826154 
C -1.772412 -2.236598 0.008715 
H -2.751390 -1.850441 -0.250400 
C -1.605752 -3.543512 0.347178 
H -2.395156 -4.284071 0.388949 
H 0.270580 3.164560 -1.884815 
H 3.305871 1.127837 1.536769 
H 2.810721 -3.388637 0.917558 
H 2.074586 -4.930063 0.414116 
H 1.907385 -4.378948 2.089088 
 
52
S11 
 
2’b 
Ru 1.311265 1.074878 -0.584596 
Cl 1.585380 0.268461 -2.853205 
O 0.199127 -4.111449 -0.092515 
O 1.756894 -0.889542 -0.016866 
S -0.923355 0.187195 -0.684385 
C 0.626566 3.105734 -0.092816 
H -0.381855 3.477768 -0.242354 
C 0.968193 2.454108 1.140894 
H 0.221299 2.332404 1.917449 
C 1.572633 3.203882 -1.140782 
C 0.832516 -1.800777 -0.152710 
C 3.210563 1.957615 0.218089 
H 4.157778 1.436866 0.303131 
C 2.875177 2.627813 -0.974360 
H 3.558666 2.608682 -1.815571 
C 1.151731 -3.148082 0.000793 
C -0.535299 -1.458826 -0.439011 
C 2.523238 -3.659617 0.274238 
C 2.238548 1.853998 1.272011 
C -1.485600 -2.508966 -0.497450 
H -2.530512 -2.298922 -0.697998 
C -1.079855 -3.797919 -0.329182 
H -1.713150 -4.674206 -0.378468 
H 1.288608 3.629337 -2.095956 
H 2.463328 1.255175 2.148550 
H 3.244729 -3.142351 -0.366324 
H 2.573882 -4.736334 0.093249 
H 2.820276 -3.464546 1.313727 
 
53
S12 
 
2’c 
Ru -1.151625 0.008824 -0.011704 
Cl -0.529393 2.337869 -0.011134 
O 3.941668 -0.150756 0.973138 
O 0.350649 -0.249553 1.414042 
O 0.559083 -0.245173 -1.247858 
C -2.257874 -1.525794 -1.124459 
H -1.829779 -2.141372 -1.909460 
C -2.175773 -1.957723 0.224155 
H -1.706814 -2.902648 0.473799 
C -2.818445 -0.250902 -1.461588 
C 1.545361 -0.198260 0.878599 
C -3.123316 0.218972 0.947565 
H -3.352854 0.924950 1.736720 
C -3.232982 0.614668 -0.423011 
H -3.527238 1.630929 -0.659553 
C 2.720385 -0.165406 1.585370 
C 1.642077 -0.218542 -0.572679 
H 2.801174 -0.138805 2.662921 
C -2.571788 -1.052529 1.257840 
C 2.937307 -0.230092 -1.158556 
H 3.037444 -0.248889 -2.237712 
C 4.048836 -0.181882 -0.362313 
C 5.469139 -0.148971 -0.830593 
H -2.819485 0.089184 -2.490771 
H -2.372576 -1.307805 2.293789 
H 5.966748 0.766294 -0.489553 
H 5.512981 -0.184888 -1.921247 
H 6.031111 -0.998978 -0.426422 
 
54
S13 
 
2’d 
Ru -1.231863 -0.015157 0.007590 
Cl -0.680801 -1.222759 2.034205 
O 3.968665 -0.986851 -0.720975 
O 0.377358 -1.042998 -0.849886 
S 0.513373 1.524754 0.621406 
C -2.773611 1.547767 -0.079924 
H -2.692489 2.531021 0.371626 
C -2.293755 1.339614 -1.417663 
H -1.852753 2.162051 -1.969024 
C -3.285753 0.467857 0.678823 
C 1.588285 -0.647267 -0.580181 
C -2.805744 -1.071592 -1.187955 
H -2.726602 -2.079703 -1.578384 
C -3.305278 -0.848522 0.109910 
H -3.593579 -1.689516 0.729834 
C 2.694119 -1.386209 -0.959248 
C 1.849064 0.600079 0.103658 
H 2.645964 -2.341401 -1.462920 
C -2.279022 0.030414 -1.945517 
C 3.196325 0.981885 0.304096 
H 3.425140 1.914838 0.807563 
C 4.226396 0.175746 -0.102890 
C 5.687667 0.435654 0.076102 
H -3.576341 0.612269 1.712226 
H -1.806202 -0.160367 -2.903074 
H 6.148853 -0.346781 0.690023 
H 5.845213 1.399357 0.564910 
H 6.203869 0.442509 -0.891019 
 
55
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3’a 
Ru 0.542595 0.869164 -1.297307 
O 0.863722 -0.284744 -3.158545 
O 0.568095 -3.801425 0.917138 
O 1.675126 -0.716227 -0.592778 
O -0.946313 -0.558204 -0.966198 
C -0.821978 2.589070 -0.990829 
H -1.905151 2.527369 -0.973834 
C -0.080028 2.336034 0.210515 
H -0.601733 2.109000 1.133685 
C -0.149981 2.801675 -2.212459 
C 0.914244 -1.712020 -0.142083 
C 2.025665 2.517168 -1.070826 
H 3.104591 2.419233 -1.115509 
C 1.280326 2.747157 -2.248637 
H 1.791765 2.805761 -3.203994 
C 1.415848 -2.816790 0.517402 
C -0.502166 -1.616212 -0.367688 
C 2.844982 -3.079115 0.837987 
C 1.334853 2.299114 0.163227 
C -1.334745 -2.678081 0.071837 
H -2.406663 -2.648670 -0.085351 
C -0.749521 -3.734996 0.701903 
H -1.267748 -4.603953 1.087337 
H -0.712460 2.923592 -3.131534 
H 1.895782 2.020470 1.049194 
H 0.060002 -0.792540 -3.374001 
H 1.532081 -0.938949 -2.873121 
H 3.434668 -2.181570 0.643601 
H 3.242332 -3.898571 0.225732 
H 2.957788 -3.368209 1.888475 
 
56
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3’b 
Ru 0.417749 1.437329 -0.680957 
O 0.690447 0.616449 -2.732596 
O -0.353340 -3.657867 0.631411 
O 1.066015 -0.499848 -0.284624 
S -1.720534 0.389320 -0.716314 
C -0.337352 3.517909 -0.403714 
H -1.318483 3.886937 -0.682231 
C -0.140818 2.892866 0.870979 
H -0.976230 2.782742 1.553723 
C 0.724806 3.554930 -1.331917 
C 0.165310 -1.433785 -0.029450 
C 2.209943 2.427504 0.272977 
H 3.156077 1.951336 0.506673 
C 2.013185 3.027914 -0.982714 
H 2.808169 3.021037 -1.720745 
C 0.564343 -2.692832 0.417590 
C -1.230471 -1.190308 -0.215629 
C 1.968525 -3.116537 0.666736 
C 1.117229 2.334539 1.198702 
C -2.140883 -2.246358 0.023592 
H -3.207721 -2.109826 -0.114418 
C -1.662220 -3.452238 0.441511 
H -2.251814 -4.332234 0.662687 
H 0.557153 3.944916 -2.330248 
H 1.244199 1.800222 2.134027 
H -0.177494 0.357521 -3.096427 
H 1.154013 -0.220284 -2.529789 
H 2.397713 -3.596155 -0.223470 
H 2.010656 -3.837722 1.487722 
H 2.581348 -2.244516 0.903923 
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S16 
 
3’c 
Ru 0.582223 1.957559 -0.498825 
O 0.859757 0.932151 -2.440570 
O 0.261203 -2.871958 1.328016 
O 1.598215 0.254869 0.097622 
O -1.006426 0.610536 -0.291805 
C -0.655681 3.696221 0.076705 
H -1.735105 3.675683 0.187099 
C 0.172687 3.307771 1.179375 
H -0.274819 3.026118 2.125950 
C -0.086422 3.994761 -1.181372 
C 0.769416 -0.719394 0.453009 
C 2.165405 3.512222 -0.271452 
H 3.229648 3.372889 -0.424125 
C 1.327409 3.875317 -1.353039 
H 1.754837 3.991263 -2.343935 
C 1.158750 -1.907428 1.013762 
C -0.641831 -0.517963 0.223457 
H 2.176894 -2.192962 1.242125 
C 1.576391 3.216503 0.995178 
C -1.539708 -1.555543 0.567148 
H -2.603353 -1.432255 0.399398 
C -1.055909 -2.716819 1.116914 
C -1.859491 -3.901326 1.539468 
H -0.721503 4.227425 -2.028778 
H 2.198614 2.831107 1.796408 
H 0.031021 0.494391 -2.708050 
H 1.484378 0.217220 -2.206498 
H -1.533103 -4.798667 1.001856 
H -2.920134 -3.736506 1.340989 
H -1.725601 -4.092836 2.610190 
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S17 
 
3’d 
Ru 0.891711 1.867919 -0.069241 
O 1.112943 1.254112 -2.194564 
O 0.175806 -3.340433 0.756447 
O 1.562461 -0.090642 0.117317 
S -1.245989 0.810892 -0.142065 
C 0.194553 3.956200 0.328314 
H -0.755764 4.388235 0.034662 
C 0.306125 3.230676 1.557622 
H -0.566547 3.104085 2.189322 
C 1.302562 4.012521 -0.544457 
C 0.675659 -1.050072 0.304048 
C 2.660789 2.711035 1.035862 
H 3.572769 2.173574 1.273274 
C 2.553539 3.413642 -0.177621 
H 3.384853 3.431570 -0.873982 
C 1.063216 -2.340567 0.604473 
C -0.734966 -0.804650 0.187702 
H 2.088180 -2.664877 0.727965 
C 1.523602 2.596558 1.903909 
C -1.623690 -1.886282 0.354426 
H -2.693838 -1.735548 0.265433 
C -1.147747 -3.144263 0.638183 
C -1.953464 -4.381942 0.847623 
H 1.197398 4.476450 -1.519618 
H 1.585393 1.994175 2.803528 
H 0.240101 1.020195 -2.563044 
H 1.591518 0.407967 -2.087381 
H -1.664439 -5.156755 0.128522 
H -3.017475 -4.169394 0.727863 
H -1.785476 -4.785803 1.852600 
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S18 
 
6’a 
Ru 0.666795 0.911335 -1.291045 
O 1.192454 -0.092283 -2.930925 
O 0.478820 -3.898491 0.789796 
O 1.663356 -0.647456 -0.257866 
O -0.889001 -0.575433 -1.081271 
C -0.744957 2.502950 -0.714590 
H -1.792844 2.343760 -0.479684 
C 0.219501 2.452611 0.322782 
H -0.082047 2.267869 1.347580 
C -0.358573 2.695025 -2.083365 
C 0.896989 -1.692115 -0.041895 
C 2.011859 2.628574 -1.396816 
H 3.062027 2.578196 -1.659564 
C 1.020017 2.760870 -2.410226 
H 1.321306 2.768726 -3.452336 
C 1.326847 -2.836856 0.600918 
C -0.484192 -1.631283 -0.499489 
C 2.696633 -3.070763 1.137627 
C 1.595034 2.438856 -0.039656 
C -1.315192 -2.768421 -0.261548 
H -2.347620 -2.767258 -0.591990 
C -0.788119 -3.851241 0.368876 
H -1.321800 -4.767922 0.589289 
H -1.107305 2.688597 -2.867089 
H 2.343197 2.223576 0.716819 
H 1.530155 -0.948833 -2.620310 
H 3.299705 -2.177086 0.967567 
H 3.180502 -3.922445 0.642197 
H 2.672427 -3.285990 2.213557 
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6’b 
Ru 0.586766 1.401966 -0.737999 
O 1.161099 0.539890 -2.459334 
O -0.497575 -3.664910 0.695515 
O 1.032362 -0.476585 0.155264 
S -1.570701 0.330685 -1.049646 
C -0.340369 3.314239 -0.204793 
H -1.406692 3.515194 -0.242256 
C 0.236906 2.833924 1.005978 
H -0.379420 2.666573 1.881835 
C 0.448075 3.507798 -1.383820 
C 0.129896 -1.410170 0.154133 
C 2.398260 2.575537 -0.191770 
H 3.414865 2.200393 -0.209466 
C 1.819579 3.130338 -1.360432 
H 2.391414 3.147414 -2.282199 
C 0.431647 -2.676953 0.660814 
C -1.199833 -1.194614 -0.362378 
C 1.766527 -3.062556 1.196818 
C 1.581829 2.395921 0.975006 
C -2.127104 -2.263332 -0.277679 
H -3.142656 -2.141482 -0.638768 
C -1.741089 -3.460745 0.245505 
H -2.361684 -4.341978 0.343293 
H -0.011336 3.854014 -2.302090 
H 1.994052 1.872718 1.832124 
H 0.550442 -0.188740 -2.655542 
H 1.955146 -2.587083 2.168868 
H 2.552673 -2.715310 0.518225 
H 1.833934 -4.146706 1.318228 
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6’c 
Ru 0.683632 1.979794 -0.451454 
O 1.099876 1.003903 -2.139870 
O 0.179014 -2.893896 1.426807 
O 1.584894 0.312634 0.496917 
O -0.977948 0.602034 -0.262145 
C -0.592273 3.650685 0.211440 
H -1.645597 3.563932 0.459592 
C 0.381234 3.485088 1.228659 
H 0.082130 3.284210 2.251122 
C -0.212934 3.867057 -1.155469 
C 0.750186 -0.679461 0.682441 
C 2.155258 3.589879 -0.515356 
H 3.193761 3.466585 -0.799386 
C 1.161739 3.839431 -1.504493 
H 1.446715 3.865595 -2.550881 
C 1.082714 -1.881468 1.256548 
C -0.638006 -0.504099 0.262168 
H 2.067194 -2.148317 1.615219 
C 1.745697 3.379812 0.841211 
C -1.538169 -1.589686 0.473093 
H -2.573006 -1.489642 0.165633 
C -1.098145 -2.751460 1.043201 
C -1.920933 -3.973038 1.306713 
H -0.971381 3.949199 -1.925435 
H 2.486106 3.075219 1.574262 
H 1.410027 0.124844 -1.865273 
H -1.522610 -4.834383 0.757746 
H -2.956037 -3.810520 0.998537 
H -1.906397 -4.227973 2.372724 
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6’d 
Ru 0.830690 1.932275 -0.040419 
O 0.620333 1.601591 -2.006970 
O 0.307819 -3.408883 0.486267 
O 1.558715 -0.066380 0.060701 
S -1.289649 0.775911 0.272915 
C 0.457922 4.105144 0.051779 
H -0.348833 4.626441 -0.449840 
C 0.255253 3.529133 1.348452 
H -0.718093 3.618902 1.820949 
C 1.696772 3.886108 -0.610550 
C 0.725490 -1.044480 0.236396 
C 2.481787 2.545756 1.296018 
H 3.213371 1.860826 1.713044 
C 2.715871 3.109819 -0.002236 
H 3.616506 2.860868 -0.551022 
C 1.151180 -2.362219 0.304196 
C -0.703037 -0.825378 0.374024 
H 2.182077 -2.673839 0.207255 
C 1.291112 2.815684 2.013669 
C -1.533646 -1.953220 0.575746 
H -2.604602 -1.820820 0.686180 
C -1.012687 -3.219871 0.623483 
C -1.774642 -4.491827 0.815314 
H 1.812018 4.203798 -1.641492 
H 1.113124 2.360399 2.981140 
H 0.114964 0.782002 -2.128312 
H -1.639777 -5.161203 -0.042544 
H -2.840537 -4.282109 0.929070 
H -1.425821 -5.026047 1.706951 
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Graphical Abstract 
 
Organometallic Ru–arene compounds bearing a maltol ligand were shown to be minimally 
active in vitro anticancer assays, presumably due to the formation of dimeric Ru(II) species in 
aqueous solutions, whereas thiopyrone compounds are reasonably active. Studies on the reac-
tivity to amino acids demonstrate different reactivity and stability of the pyrone and thiopy-
rone complexes, which probably renders them active against human tumor cells 
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Abstract: Organometallic Ru–arene 
compounds bearing a maltol ligand 
were shown to be nearly inactive in in 
vitro anticancer assays, presumably due 
to the formation of dimeric RuII species 
in aqueous solutions. In an attempt to 
stabilize such complexes, [Ru(η6-p-
cymene)(XY)Cl] (XY = pyrones or 
thiopyrones) compounds with different 
substitution pattern of the (thio)pyrone 
ligands were synthesized, characterized 
spectroscopically, structurally and in 
terms of their aquation behavior as well 
as their tumor-inhibiting potency. The 
aquation behavior of pyrone systems 
with electron-donating substituents and 
of thiopyrone complexes was found to 
be significantly different from that of 
the maltol-type complex reported 
earlier. However, the formation of the 
dimer can be excluded as the primary 
reason for the inactivity of the complex 
since some of the stable compounds are 
not active in cancer model systems 
either. In contrast, studies on the 
reactivity to amino acids demonstrate 
different reactivity of the pyrone and 
thiopyrone complexes, and the higher 
stability of the latter probably renders 
them active against human tumor cells. 
Keywords: Amino acids · 
Antitumor agents · Pyrone ligand · 
Ruthenium–arene complexes · 
Thiopyrone ligand
 
Introduction 
Metal complexes play an important role in the treatment of 
cancer. One of the most important and widely used compound is 
cisplatin which was developed by Rosenberg in the 1960ies.[1] 
Due to severe side effects, activity in a limited spectrum of 
tumors and the occurrence of resistance,[2] the development of 
new antitumor agents with other metal ions as central atom is an 
area of intensive research.[1,3-7] Ruthenium complexes have 
shown the most promising results in preclinical and clinical 
experiments.[8-11] NAMI-A and KP1019 are in the most advanced 
stage of development and are currently undergoing clinical trials 
(Figure 1).[8-10] The low general toxicity of these complexes 
reflects a more selective activity in tumor tissue as compared to 
platinum-based compounds, mediated by transport into the cell in 
the form of protein adducts and reduction in the tumor.[12-16]  
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Figure 1. Structures of the investigational anticancer compounds KP1019, NAMI-A, 
[Ru(η6-p-cymene)(pta)Cl2] (RAPTA-C), [Ru(arene)(acac)Cl]+, [Ru(arene)(en)Cl]+ 
and the dinuclear compound PyrRu212. 
More recently the potential of organometallic RuII–arene 
compounds as anticancer agents has been recognized.[4,7,11,17] 
This compound type bears an arene ligand which facilitates the 
diffusion through the cell membrane (and thereby enhances 
cellular uptake). The coordination sphere is filled with mono- or 
bidentate ligands, controlling the reactivity to biomolecules, and 
these moieties also appear to be determinants for the modes of 
action.[7,14,18-22] 
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RAPTA (containing the 1.3.5-triaza-7-
phoshatricyclo[3.3.1.1]decane [pta] ligand) and RuII–(arene)(en) 
complexes (en = 1,2-diaminoethane) are the best studied 
ruthenium organometallics.[4,11,23] The pta complexes have been 
shown to be, similarly to NAMI-A, active against metastasis, but 
inactive in in vitro cell assays,[24,25] whereas the en complexes 
have potential as anticancer agents against primary tumors.[26] 
Beside pta and en several other ligand systems have been studied 
in Ru-based organometallics, including moieties containing O,O, 
N,O, N,N and S,O donor sets.[19,22,27-35] The nature of the donor 
atoms was shown to influence the in vitro anticancer activity 
significantly, and the low potency of some of the synthesized 
compounds appears to be related to the instability of the Ru–
ligand interaction, causing the formation of dimeric RuII species, 
with the arene moiety remaining attached to the metal center. 
Recently, we have demonstrated that the replacement of the O,O 
donor set of maltol by S,O leads to significantly increased 
stability and the compounds are anticancer active in the low μM 
range,[34] and this ligand type found application, e.g., in the 
removal or supplementation of iron, or in imaging as contrast 
agents.[36] However, a switch from the pyrone to a pyridone 
systems in the case of that particular ligand also afforded stable 
compounds in aqueous solution with promising anticancer 
activity.[21,29,30,33]  
Herein, the synthesis and characterization of a series of 
(thio)pyrone derived RuII–cymene complexes is described and 
compared to recent results.[34] The molecular structures of the 
complexes with kojic acid, allomaltol, pyromeconic acid and 
maltol were determined by single crystal X-ray diffraction 
analysis. The aquation behavior and the interactions with small 
biomolecules were investigated, and the cytotoxic activity in 
different human cancer cell lines was studied. The influence of 
the substitution pattern of the (thio)pyrone moiety on the stability 
of the complexes and the anticancer activity in human tumor cell 
lines is discussed. 
Results and Discussion 
Synthesis: The synthesis of the ligand 1b (allomaltol) was 
achieved in two steps, starting from kojic acid 1a by reaction 
with thionyl chloride, followed by a reductive step using Zn/HCl 
(60%; Scheme 1).[37] Ligand 1e was obtained by conversion of 
1b with formaldehyde under alkaline conditions (70%).[37] The 
thiopyrones 1g and 1d were prepared by reaction of P4S10 with 
the corresponding pyrones 1b and 1d (40-60%).[38] Ligands 1a–h 
were converted with bis[dichlorido(η6-p-cymene)ruthenium(II)] 
under alkaline conditions into the respective RuII complexes 2a–
h in good yields (61–85%) (Scheme 1).[39] The reaction was 
performed with a slight excess of ligand to facilitate the 
purification step.  
All complexes were characterized by 1D and 2D NMR 
spectroscopy, mass spectrometry and elemental analysis. The 
influence of the solvent on the inversion of the Ru center is 
significant: In protic solvents, fast inversion of the Ru center was 
observed, which resulted in the formation of two doublets for the 
p-cymene ligand, whereas in CDCl3, the aromatic protons are 
detected as four doublets. A similar behavior was also observed 
in the 13C NMR spectra, which is in agreement with related RuII–
arene complexes.[39] In the 1H NMR spectrum of 2e in CDCl3, 
two doublets with a coupling constant of 17 Hz were observed, 
which were assigned to the protons of the CH2 group (see 
Supporting Information). This geminal splitting can be explained 
by the formation of an intramolecular hydrogen bond between 
the hydroxymethyl moiety and the coordinated O3 atom. ESI 
mass spectra were recorded in methanol, and the predominant 
peak for the complexes 2a–h was assigned to [M – Cl]+ ions 
(good agreement of the observed and theoretical isotopic pattern). 
Scheme 1. Synthesis of ligands i) SOCl2; ii) Zn/HCl; iii) formaldehyde, NaOH; iv) 
P4S10, dioxane; v) [Ru(η6-p-cymene)Cl2]2, NaOMe; vi) H2O; vii) nucleophiles (Nu) 
such as 5’-GMP or amino acids. 
Molecular structure determination: Single crystals suitable 
for X-ray diffraction analysis were obtained for the RuII 
complexes 2a, 2c and 2d by recrystallization from ethyl acetate 
(Figure 2). The compounds crystallized in the monoclinic P21/n 
(2a), P21/c (2d) and triclinic P-1 (2c) space groups, respectively. 
All complexes have piano-stool configuration. The pyrone 
ligands act as bidentate and form a five-membered chelate cycle 
with an envelope-like conformation on binding to ruthenium. The 
Ru–Cl bond lengths are in the same range as those of recently 
published compounds [2.4200(11)–2.4273(8) Å].[29,32] The 
largest torsion angle Ru–O1–C–C (12°) was found for 2c.  
Figure 2. Molecular structures of the RuII complexes 2a (top left), 2c (top right) and 
2d (bottom). 
O
HO
O
OH
i, ii
O
O
OH
O
O
OH
OH
O
O
OH
O
S
OH
iii iv1a 1b
1e 1f 1g
1c
1d
1h
1a-h
O
O
OH
O
O
OH
O
S
OH
iv
OR
X
OH
R'
v
O
X
O
Ru
Cl
R'R
vi
O
X
O
Ru
OH2
R'R
vii
O
X
O
Ru
Nu
R'R
2a-h 3a-h 4a-h
++
68
 3
In contrast to a crystal structure report for 2d,[19] the two Ru–
O bonds in 2a, 2c and 2d were found to be slightly different, and 
the Ru–O1 distance is marginally shorter than the Ru–O2 bond. 
The largest difference was found for 2d, with bond lengths of 
2.078(2) (Ru–O1) and 2.117(2) Å (Ru–O2). For complexes 2c 
and 2d short contacts between two independent molecules were 
found. The H2 of the arene and one proton of the isopropyl group 
have short contacts to the O3 of the neighboring molecule. 
Intermolecular hydrogen bonds between the hydroxymethyl 
group and the O3 of the neighboring molecule were observed for 
2a. The R- and the S-stereoisomers of 2a are connected in 
alternating manner via hydrogen bonds, forming a syndiotactic 
chain (Figure 2). The distance between the O3 of the R-
enantiomer to the –OH group of the S-isomer is 1.969 Å, whereas 
the length of the hydrogen bond of the S-O3 to the R-OH is 
1.931 Å. Connections between adjacent chains via short contacts 
of the isopropyl protons to O1 (2.527 Å) and p-cymene (2.983 Å) 
are responsible for the observed layer-type structure (see 
Supporting Information).  
Aquation: Aquation and stability in water were investigated 
by means of 1H NMR spectroscopy. Due to the higher 
lipophilicity of the thiopyrone complexes, all experiments for 2g 
and 2h were performed in 10% [D6]DMSO/D2O solutions. No 
coordination of [D6]DMSO was observed in preliminary 
experiments, although small amounts of degradation products 
were detected after 18 h in this solvent mixture.  
The complexes 2a–h hydrolyze in aqueous solution within 
seconds to the charged complexes 3a–h by exchange of the 
chlorido ligand by a neutral water molecule, and identical NMR 
spectra were obtained after induced release of the chlorido 
ligands by equimolar amounts of AgNO3. NMR experiments 
with 2b in physiological NaCl solution (100 mM), which should 
shift the aquation equilibrium back from 3b to 2b,[40] showed no 
influence on the aquation process. For complexes 3a–d, the 
formation of the identical dimeric hydrolysis side product 
[Ru2(cym)2(OH)3]+ was observed (detected in positive ion mode 
ESI mass and 1H NMR spectra), which is thought to be 
responsible for the inactivity of the compound type against 
cancer cells.[19] The amount of formed side product depends on 
the concentration, the incubation time and the pH value of the 
solution. In contrast to 3a–d, compounds 3e–h are stable for 
more than 24 h in aqueous solution. 
In order to stabilize the complexes against hydrolysis and the 
concomitant dimer formation, 2a–d were reacted with imidazole 
in aqueous solution to form the corresponding positively charged 
complex. The reactions proceeded very quickly (within seconds), 
and the resulting imidazole complexes did not show the 
formation of a dimeric species within 18 h (Figure 3). 
The pKa values of 3a–f were determined by stepwise 
deprotonation of the aqua species with NaOD. The chemical 
shifts of the p-cymene protons were monitored by 1H NMR 
spectroscopy and plotted against the pH value of the solution to 
give the pKa values (corrected as reported recently;[32] see 
Table 1 and Supporting Information). The pKa values of the 
thiopyrone complexes 3g and 3h were not detectable due to 
precipitation of the complexes at pH 10.0; however, the 
theoretical values obtained by DFT calculation are 12.8 and 12.5 
for 3g and 3h, respectively. The pKa values for 3a–f are 
comparable to those published recently for other pyrone- and 
pyridone-based RuII–arene complexes (8.99–9.64).[19,32,33] The 
pKa values implicate that 3a–h are present as reactive aqua 
species under physiological conditions.  
 
Figure 3. 1H NMR spectra of the reaction of 3c with imidazole. (a) 3c in D2O after 
5 min, (b) 3c after 18 h, (c) imidazole/3c reaction mixture after 5 min (molar ratio 
1 : 1) and (d) imidazole/3c reaction mixture after 18 h. 
Cytotoxicity: Cytotoxic activity was assayed in the human 
tumor cell lines SW480 (colon carcinoma), CH1 (ovarian 
carcinoma) and A549 (non-small lung carcinoma) by means of 
the colorimetric MTT assay (Table 1). It should be noted that the 
chlorido complexes 2a–h applied to the medium are rapidly 
converted into the corresponding aqua complexes 3a–h prior to 
contact with cells. The recently reported maltol complex 2d does 
not exhibit activity in human tumor cells to a relevant extent. 
This behavior has been thought to be related to the formation of 
the inactive [Ru2(p-cymene)2(OH)3]+ in aqueous solution.[19,29] 
Similarly, the structurally related compounds 2a–c show no 
relevant cytotoxic activity in the tested cell lines.  
Table 1. pKa values of 3a–h and IC50 values of 2a–h (96 h exposure). 
Complex pKa 
IC50 [μM] 
CH1 SW480 A549 
a 8.93 ± 0.02  234 ± 21 429 ± 10 n.d. 
b [34] 9.01 ± 0.03  239 ± 22 359 ± 119 518 ± 65 
c 8.91 ± 0.02  112 ± 50 206 ± 94 490 ± 43 
d [34] 9.23 [19] 81 ± 14 159 ± 41 482 ± 20  
e 8.92 ± 0.02  242 ± 39 457 ± 33 510 ± 29 
f 9.12 ± 0.04  81 ± 8 165 ± 31 389 ± 37 
g [34] >10 (12.8 a) 35 ± 8  20 ± 7 n.d. 
h [34] >10 (12.5 a) 13 ±  4 5.1 ± 0.5 n.d. 
a obtained by DFT calculation. 
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In contrast to 2a–d, 2e–h do not form such dimeric species. 
However, the in vitro activity of 2e and 2f was in a similar 
dimension as that of 2a–d. Switching from pyrone to the 
analogous thiopyrone compounds 2g and 2h results in IC50 
values in the low μM range. Notably these compounds are more 
active in the SW480 cell line than in the otherwise more 
chemosensitive CH1 cells. This data set suggests that dimer 
formation is not responsible for the inactivity of 2a–f (Table 1).  
Reaction with small biomolecules: The interactions of the 
aqua species 3a–h with small biomolecules, like the DNA model 
compound 5’-GMP and amino acids, were investigated by 1H 
NMR spectroscopy.  
The reaction of 5’-GMP can easily be monitored in 1H NMR 
spectroscopy due to the shift of the N7 atom of 5’-GMP from 8.1 
to approximately 7.9.[41] The reaction was completed within 
seconds, and the formed adducts were stable in solution for more 
than 18 h. Accordingly, DNA is a possible target for this kind of 
RuII-cymene complexes, as suggested for related organometallic 
ruthenium(II) compounds.[19]  
 
Figure 4. The reactions of 3a and 3e–h with glycine to 4a and 4e–h monitored by 
1H NMR spectroscopy for 18 h. 
However, many drugs are administered intravenously, and 
amino acids and proteins are the first potential binding partners 
for the complexes in the bloodstream. Therefore, the reaction 
with the amino acids glycine, L-histidine, L-methionine and L-
cysteine was investigated to gain insight into possible 
interactions with proteins and pharmacokinetic pathways. 
Complexes 3a–h were treated with an equimolar amount of the 
respective amino acid, and the reaction progress was monitored 
for 18 h. The addition of L-cysteine led to fast decomposition of 
all complexes within minutes, most probably due to the strong 
trans-effect exhibited by the thiol functionality. The reactions of 
the pyrone-derived complexes 3a–f with L-methionine, L-
histidine and glycine to give 4a–f differ significantly from those 
of the thiopyrone complexes 3g and 3h. All compounds reacted 
immediately with 1 eq L-methionine by replacing the aqua ligand 
with the amino acid (bound via the thioether moiety; see below). 
In the case of 3a–f, the pyrone ligands 1a–f were cleaved off 
quantitatively by the amino acid within 18 h. In contrast, 4g and 
4h were stable in solution over the analysis time and no free 
ligands were detected. Similar results were obtained for the 
reaction with L-histidine. All Ru(II) centers coordinated to the 
amino acid at a ratio of 1 : 1 via the N1 or N3 atoms of the 
imidazole moiety. As in the case with L-Met, the pyrone ligands 
1a–f were released upon coordination of the amino acid, whereas 
for 3g and 3h stable species were obtained. The reaction of 
glycine with 3a–h was significantly slower than with the other 
investigated amino acids: after 18 h incubation time, the 1H NMR 
spectra of reaction mixtures showed the formation of two 
doublets at approximately 3.1 ppm with a geminal coupling of 
17 Hz (Figure 4). Those signals were assigned to the CH2 group 
of glycine which acts as a chelating ligand and is coordinated via 
the amino and the carboxylic group to the Ru(II) center to form a 
five-membered ring structure. No adducts of 3g and 3h with 
glycine were observed, probably due to the inability of bidentate 
coordination of the amino acid. This also demonstrates the higher 
stability of the thiopyrone complexes.  
Notably, no ruthenium dimer signals (at approximately 5.0 
and 5.5 ppm) were observed in the NMR experiments within 18 h, 
when amino acids were present. The high reactivity to amino 
acids and the prevention of the formation of dimeric species by 
coordination to amino acids make it unlikely that the 
dimerization is the reason for the anticancer inactivity of the 
maltol complex and the related pyrone-based compounds. In 
contrast, the slower degradation in presence of amino acids might 
allow the thiopyrone complexes to enter the cells to a higher 
degree in their unmodified form.  
In order to characterize the coordination compound 
obtained upon reaction of 3c with L-methionine by NMR 
spectroscopy, 3c was reacted with an equimolar amount of the L-
Met analogous Se-methyl-L-selenocysteine. 1H, 13C and 77Se 
NMR spectra were recorded over a period of 18 h. The selenium 
signal of Se-methyl-L-selenocysteine at -419 ppm vanished 
within 10 min after addition of 3c, and two new signals at -283 
and -265 ppm appeared (Figure 5 and Supporting Information). 
The signal at -283 ppm disappears over time, probably due to 
completion of the N,Se-chelation to the RuII center (Figure 5, C). 
The 13C NMR spectrum contained after 18 h signals at 176.3 ppm, 
assignable to the carbonyl functionality of the free pyrone, and at 
180.5 ppm, which corresponds to the uncoordinated carboxylate 
of the amino acid. Therefore it is proposed that the amino acid 
binds in a bidentate fashion via Se and N to the RuII center under 
release of the pyrone ligand. 
 
Figure 5. Time course of the reaction of Se-methyl-L-selenocysteine (A) with 3c 
followed by 77Se NMR spectroscopy. (a) Se-methyl-L-selenocysteine, (b) Se-
methyl-L-selenocysteine/3c reaction mixture after 5 min and (c) after 18 h to form 
the intermediate [Ru(cym)(Se-methyl-L-selenocysteine-κSe)(1c)] (B) and eventually 
[Ru(cym)(Se-methyl-L-selenocysteine-κ2N,Se)(D2O)] (C). 
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In an attempt to overcome the rapid decomposition of 3g and 
3h in the presence of L-cysteine, the chlorido ligands in the RuII 
complexes were exchanged by L-histidine in situ. The new 
compounds were, similarly to the reactions with imidazole, 
significantly more stable under the applied conditions, and no 
degradation products were observed in the 1H NMR spectra after 
addition of an equimolar amount of L-cysteine (monitored for 
18 h).  
Conclusion 
Bioorganometallic chemistry is an emerging topic of research, 
and especially the use of Ru–arene compounds as anticancer 
agents appears promising. The Ru–arene complex with the O,O-
bound maltol ligand was shown to be inactive in in vitro 
anticancer assays. The inactivity of the compound was assumed 
to be related to the formation of dimeric RuII species in aqueous 
solutions.[19] In contrast, the analogous thiomaltol complexes 
exhibit anticancer activity in the low μM range and are not prone 
to the dimer formation.[34] The formation of the dimeric species 
can also be inhibited by modification of the substitution pattern 
of the pyrone scaffold. The introduction of electron-donating 
groups leads to compounds with higher stability. However, these 
compounds were found to be also inactive in vitro, demonstrating 
that the dimer formation is not the main factor for the inactivity 
of the compound type. The aquation of the Ru center appears to 
be a prerequisite for the release of the pyrone ligands, and 
replacement of the chlorido ligand by imidazole was shown to be 
an effective additional option to obtain RuII–(arene)(pyrone) 
complexes stable in aqueous solutions. 
In order to gain deeper insight into the chemical behavior of 
these compounds, reactions with the amino acids Gly, L-His, L-
Met and L-Cys were followed by NMR spectroscopy. These 
studies revealed a significantly higher stability of the thiopyrone 
complexes. This property gives them more time to be taken up 
into the tumor cells, whereas the pyrone complexes decompose to 
compound mixtures involving amino acid coordination. It is 
assumed that N,O and S,O chelates are thermodynamically 
preferred over the O,O coordination of pyrone ligands, causing 
the release of the pyrone ligand if appropriate molecules are 
present, as is the case in a biological environment. 
Experimental Section 
All solvents were dried and distilled prior to use.[42] Ruthenium(III) chloride 
(Johnson Matthey), kojic acid 1a (Fluka), maltol 1d (Aldrich), ethylmaltol 1f 
(Aldrich), formaldehyde solution (Aldrich), P4S10 (Aldrich) and sodium methoxide 
(Aldrich) were purchased and used without further purification. Bis[dichlorido(η6-p-
cymene)ruthenium(II)], 2-chloromethyl-5-hydroxypyran-4(1H)-one (chlorokojic 
acid), 5-hydroxy-2-methyl-pyran-4(1H)-one (1b), 3-hydroxy-pyran-4(1H)-one (1c), 
2-hydroxymethyl-3-hydroxy-6-methyl-pyran-4(1H)-one (1e), 5-hydroxy-2-methyl-
pyran-4(1H)-thione (1g) and 3-hydroxy-2-methyl-pyran-4(1H)-thione (1h) were 
synthesized as described elsewhere.[37,38] Melting points were determined with a 
Büchi B-540 apparatus and are uncorrected. Elemental analyses were carried out 
with a Perkin Elmer 2400 CHN Elemental Analyzer at the Microanalytical 
Laboratory of the University of Vienna. NMR spectra were recorded at 25 °C using 
a Bruker FT-NMR spectrometer Avance IIITM 500 MHz at 500.10 MHz (1H), 
125.75 MHz (13C) , 202.44 MHz (31P) and 95.38 MHz (77Se, referenced to diphenyl 
diselenide) in [D6]DMSO, D2O or CDCl3. The 2D NMR spectra were measured in a 
gradient-enhanced mode. An esquire3000 ion trap mass spectrometer (Bruker 
Daltonics, Bremen, Germany), equipped with an orthogonal ESI ion source, was 
used for MS measurements. The solutions were introduced via flow injection using 
a Cole-Parmer 74900 single-syringe infusion pump (Vernon Hills, IL).  
X-ray diffraction measurements were performed with single crystals of 2a–d on a 
Bruker X8 APEXII CCD diffractometer at 100 K. The single crystals were 
positioned at 40 mm from the detector and measured under the following 
conditions: (2a) 2710 frames for 5 sec over 2°, (2b) 622 frames for 20 sec over 2°, 
(2c) 1007 frames for 10 sec over 1° and (2d) 2173 frames for 4 sec over 1°. The 
data were processed using the SAINT software package.[43] Crystal data, data 
collection parameters, and structure refinement details are given in Table S1–S4 
(Supporting Information). The structures were solved by direct methods and refined 
by full-matrix least-squares techniques. Non-hydrogen atoms were refined with 
anisotropic displacement parameters. H atoms were inserted at calculated positions 
and refined with a riding model. The following computer programs were used: 
structure solution, SHELXS-97;[44] refinement, SHELXL-97;[45] molecular diagrams, 
ORTEP-3;[46] computer, Pentium IV; scattering factors.[47] Crystallographic data for 
the structural analysis has been deposited with the Cambridge Crystallographic Data 
Centre, CCDC No. 739426 for 2a, CCDC No. 739427 for 2c, CCDC No. 739425 
for 2d. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
General procedure for the synthesis of the ruthenium(II)(η6-p-cymene) 
complexes: Ligand (1 eq) and sodium methoxide were dissolved in methanol and 
stirred for 5 min under inert atmosphere (clear solution). A solution of [Ru(η6-p-
cymene)Cl2]2 in MeOH/CH2Cl2 (1 : 1) was added, and the reaction mixture was 
stirred for 5–18 h. The reaction mixture was concentrated under reduced pressure, 
and the residue was extracted with CH2Cl2. The combined organic layers were 
filtered, and the solvent was removed. The crude product was purified by 
recrystallization. 
Chlorido[2-hydroxymethyl-5-(oxo-κO)-4-(1H)-pyronato-κO4](η6-p-cymene)-
ruthenium(II) (2a): The reaction was performed according to the general 
complexation protocol, using 1a (113.2 mg, 0.73 mmol, 1 eq), NaOMe (43 mg, 
0.8 mmol, 1.1 eq) and [Ru(η6-p-cymene)Cl2]2 (200 mg, 0.33 mmol, 0.45 eq). The 
crude product was recrystallized from acetone/n-hexane, affording an orange 
powder (200 mg, 67%). Single crystals were grown from ethyl acetate, suitable for 
X-ray diffraction analysis. Mp: > 180 °C (decomp.); 1H NMR (500.10 MHz, 
CDCl3):  = 1.31 (d, 3J(H,H) = 7 Hz, 6H, CH3,Cym), 2.29 (s, 3H, CH3,Cym), 2.90 (m, 
1H, CHCym), 3.83 (bs, 1H, OH), 4.40 (d, 2J(H,H) = 17 Hz 1H, CH2), 4.46 (d, 2J(H,H) 
= 17 Hz 1H, CH2), 5.30 (dd, 3J(H,H) = 5 Hz, 3J(H,H) = 5 Hz, 2H, H3/H5Cym), 5.53 
(dd, 3J(H,H) = 5 Hz, 3J(H,H) = 5 Hz, 2H, H2/H6Cym), 6.63 (s, 1H, H3), 7.65 (s, 1H, 
H6); 13C NMR (125.75 MHz, CDCl3) : 18.6 (CH3,Cym), 22.3 (CH3,Cym), 31.1 
(CHCym), 60.7 (CH2), 78.0 (C3/C5Cym), 79.6 (C2/C6Cym), 95.6 (C4Cym), 100.1 
(C1Cym), 107.5 (C3), 141.1 (C6), 159.3 (C2), 167.9 (C5), 185.7 (C4); elemental 
analysis calcd for C16H19ClO4Ru: C 46.66 H 4.65; found C 46.43 H 4.56. 
Chlorido[2-methyl-5-(oxo-κO)-4-(1H)-pyronato-κO4](η6-p-cymene)-
ruthenium(II) (2b): The reaction was performed according to the general 
complexation procedure, using 1b (98 mg, 0.73 mmol, 1 eq), NaOMe (43 mg, 
0.8 mmol, 1.1 eq) and [Ru(η6-p-cymene)Cl2]2 (200 mg, 0.33 mmol, 0.45 eq). The 
crude product was recrystallized from MeOH/n-hexane, affording a deep red 
crystalline solid (207 mg, 73%). Single crystals were grown from ethyl acetate, 
suitable for X-ray diffraction analysis. Mp: > 200 °C (decomp.); 1H NMR 
(500.10 MHz, CDCl3):  = 1.33 (d, 3J(H,H) = 7 Hz, 6H, CH3,Cym), 2.26 (s, 3H, CH3), 
2.32 (s, 3H, CH3,Cym), 2.93 (m, 1H, CHCym), 5.32 (dd, 3J(H,H) = 5 Hz, 3J(H,H) = 
5 Hz, 2H, H3/H5Cym), 5.53 (dd, 3J(H,H) = 5 Hz, 3J(H,H) = 5 Hz, 2H, H2/H6Cym), 
6.34 (s, 1H, H3), 7.66 (s, 1H, H6); 13C NMR (125.75 MHz, CDCl3):  = 18.6 
(CH3,Cym), 19.8 (CH3), 22.3 (CH3,Cym), 31.1 (CHCym), 78.8 (C3/C5Cym), 79.8 
(C2/C6Cym), 95.6 (C4Cym), 100.1 (C1Cym), 109.6 (C3), 141.1 (C6), 159.3 (C2), 165.2 
(C5), 185.7 (C4); elemental analysis calcd (%) for C16H19ClO3Ru·0.25 H2O: C 
48.00, H 4.91 found: C 47.94, H 4.76. 
Chlorido[3-(oxo-κO)-4-(1H)-pyronato-κO4](η6-p-cymene)ruthenium(II) (2c): 
The reaction was performed according to the general complexation procedure, using 
pyromeconic acid (81 mg, 0.72 mmol, 1 eq), NaOMe (43 mg, 0.8 mmol, 1.1 eq) 
[Ru(η6-p-cymene)Cl2]2 (200 mg, 0.326 mmol, 0.45 eq). The crude product was 
recrystallized from ethyl acetate/n-hexane, affording a deep red crystalline solid 
(202 mg, 73%). Single crystals were grown from ethyl acetate, suitable for X-ray 
diffraction analysis. Mp: > 200 °C (decomp.); 1H NMR (500.10 MHz, CDCl3):  = 
1.34 (d, 3J(H,H) = 7 Hz, 6H, CH3,Cym), 2.32 (s, 3H, CH3,Cym), 2.90-2.96 (m, 1H, 
CHCym), 5.32 (dd, 3J(H,H) = 5 Hz, 3J(H,H) = 5 Hz, 2H, H3/H5Cym); 5.55 (dd, 
3J(H,H) = 5 Hz, 3J(H,H) = 5 Hz, 2H, H2/H6Cym), 6.57 (d, 3J(H,H) = 7 Hz, 1H, H5), 
7.66 (d, 3J(H,H) = 7 Hz, 1H, H6), 7.77 (s, 1H, H2); 13C NMR (125.75 MHz, 
CDCl3):  = 18.6 (CH3,Cym), 22.3 (CHCym), 31.1 (CH3,Cym), 76.9 (C3/C5Cym), 79.6 
(C2/C6Cym), 95.6 (C4Cym), 100.1 (C1Cym), 111.4 (C5), 142.6 (C2), 153.8 (C6), 161.0 
(C3), 185.3 (C4); elemental analysis calcd (%) for C15H17ClO3Ru·0.5 H2O: C 46.10, 
H 4.64; found C 45.92, H 4.37. 
Chlorido[2-methyl-3-(oxo-κO)-4-(1H)-pyronato-κO4](η6-p-cymene)-
ruthenium(II) (2d): The reaction was performed according to the general 
complexation procedure, using 1d (98 mg, 0.73 mmol, 1 eq), NaOMe (43 mg, 
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0.8 mmol, 1.1 eq) and [Ru(η6-p-cymene)Cl2]2 (200 mg, 0.33 mmol, 0.45 eq). The 
crude product was recrystallized from ethyl acetate/n-hexane, affording a deep red 
crystalline solid (164 mg, 64%). Single crystals were grown from ethyl acetate, 
suitable for X-ray diffraction analysis. Mp: > 200 °C (decomp.); 1H NMR 
(500.10 MHz, CDCl3):  = 1.32 (d, 3J(H,H) = 7 Hz, 6H, CH3,Cym), 2.32 (s, 3H, CH3), 
2.41 (s, 3H, CH3), 2.91 (m, 1H, CHCym), 5.30 (dd, 3J(H,H) = 6 Hz, 3J(H,H) = 6 Hz, 
2H, H3/H5Cym), 5.52 (dd, 3J(H,H) = 6 Hz, 3J(H,H) = 6 Hz, 2H, H2/H6Cym), 6.51 (d, 
3J(H,H) = 5 Hz, 1H, H5), 7.56 (d, 3J(H,H) = 5 Hz, 1H, H6); 13C NMR (125.75 MHz, 
CDCl3):  = 14.6 (CH3), 18.6 (CH3,Cym), 22.3 (CH3,Cym), 31.1 (CHCym), 77.8 
(C3/C5Cym), 79.6 (C2/C6Cym), 95.8 (C4Cym), 99.7 (C1Cym), 111.1 (C5), 151.7 (C6), 
153.9 (C2), 157.8 (C3), 182.7 (C4); elemental analysis calcd (%) for C16H19ClO3Ru: 
C 48.55, H 4.84; found C 48.45, H 4.63.  
Chlorido[2-hydroxymethyl-6-methyl-3-(oxo-κO)-4-(1H)-pyronato-κO4](η6-p-
cymene)ruthenium(II) (2e): The reaction was performed according to general 
complexation protocol, using 2-hydroxymethyl-3-hydroxy-6-methyl-pyran-4(1H)-
one 1e (113 mg, 0.73 mmol, 1 eq), NaOMe (43 mg, 0.8 mmol, 1.1 eq) and [Ru(η6-p-
cymene)Cl2]2 (200 mg, 0.33 mmol, 0.45 eq). The crude product was recrystallized 
from ethyl acetate/n-hexane, affording a red crystalline solid (250 mg, 81%). Mp: 
193–196 °C (decomp.); 1H NMR (500.l0 MHz, CDCl3):  = 1.33 (d, 3J(H,H) = 7 Hz, 
6H, CH3,Cym), 2.27 (s, 3H, CH3,Cym), 2.31 (s, 3H, CH3,Cym), 2.88 (m, 1H, CHCym), 
4.05 (brs, 1H, OH), 4.63 (d, 2J(H,H) = 14 Hz, 1H, CH2), 4.80 (d, 2J(H,H) = 14 Hz, 
1H, CH2), 5.30 (dd, 3J(H,H) = 4 Hz, 3J(H,H) = 4 Hz, 2H, H3/H5Cym), 5.53 (dd, 
3J(H,H) = 6 Hz, 3J(H,H) = 6 Hz, 2H, H2/H6Cym), 6.31 (s, 1H, H5); 13C NMR 
(125.75 MHz, CDCl3):  = 19.1 (CH3,Cym), 20.3 (CH3), 22.8 (CH3,Cym), 31.5 (CHCym), 
59.4 (CH2), 78.1 (C3/C5Cym), 80.3 (C2/C6Cym), 96.2 (C4Cym), 100.0 (C1 Cym), 109.9 
(C5), 152.1 (C6), 156.5 (C2), 164.5 (C3), 185.3 (C4); elemental analysis calcd (%) 
for C17H21ClO4Ru: C 47.94, H 4.97; found C 48.00, H 5.02. 
Chlorido[2-ethyl-3-(oxo-κO)-4-(1H)-pyronato-κO4](η6-p-cymene)ruthenium(II) 
(2f): The reaction was performed according to the general complexation procedure, 
using ethylmaltol 1g (102 mg, 0.72 mmol, 1 eq), NaOMe (43 mg, 0.8 mmol, 1.1 eq) 
and [Ru(η6-p-cymene)Cl2]2 (200 mg, 0.33 mmol, 0.45 eq). The crude product was 
dissolved in a minimum amount of CH2Cl2 and precipitated with diethyl ether, 
affording a deep red solid (181 mg, 61%). Mp: > 140 °C (decomp.); 1H NMR 
(500.10 MHz, CDCl3):  = 1.22 (t, 3J(H,H) = 7 Hz, 3H, CH3,Cym), 1.32 (d, 3J(H,H) = 
7 Hz, 6H, CH3,Cym), 2.34 (s, 3H, CH3), 2.80 (m, 1H, CHCym), 2.91 (q, 3J(H,H) = 7 Hz, 
2H, CH2), 5.30 (dd, 3J(H,H) = 6 Hz, 3J(H,H) = 6 Hz, 2H, H3/H5Cym), 5.52 (dd, 
3J(H,H) = 6 Hz, 3J(H,H) = 6 Hz, 2H, H2/H6Cym), 6.52 (d, 3J(H,H) = 5 Hz, 1H, H5), 
7.59 (d, 3J(H,H) = 5 Hz, 1H, H6); 13C NMR (125.75 MHz, CDCl3):  = 10.8 (CH3), 
18.6 (CH3,Cym), 21.6 (CH2), 22.3 (CH3,Cym), 31.1 (CHCym), 77.8 (C3/C5Cym), 79.6 
(C2/C6Cym), 95.9 (C4Cym), 99.6 (C1Cym), 111.0 (C5), 151.6 (C6), 157.3 (C2), 158.3 
(C3), 182.9 (C4); elemental analysis calcd (%) for C17H21ClO3Ru: C 49.81, H 5.16; 
found C 49.49, H 5.10.  
Chlorido[2-methyl-5-(oxo-κO)-pyran-4(1H)-thionato-κS](η6-p-cymene)-
ruthenium(II) (2g): The reaction was performed according to the general 
complexation protocol, using thioallomaltol 1g (103 mg, 0.72 mmol, 1 eq), NaOMe 
(43 mg, 0.8 mmol, 1.1 eq) and [Ru(η6-p-cymene)Cl2]2 (200 mg, 0.33 mmol, 0.45 eq). 
The crude product was recrystallized from ethyl acetate/n-hexane, affording a red 
crystalline solid (230 mg, 85%). Mp: > 190 °C (decomp.); 1H NMR (500.10 MHz, 
CDCl3):  = 1.26 (d, 3J(H,H) = 7 Hz, 6H, CH3), 2.23 (s, 3H, CH3,Cym), 2.27 (s, 3H, 
CH3), 2.76 (m, 1H, CHCym), 5.51 (d, 3J(H,H) = 5 Hz, 2H, H3´/H5´); 5.71 (d, 3J(H,H) 
= 6 Hz, 2H, H2´/H6´), 7.09 (s, 1H, H5), 7.87 (s, 1H, H2); 13C NMR (125.75 MHz, 
CDCl3):  = 18.6 (CH3,Cym), 19.0 (CH3), 22.1 (CH3,Cym), 30.9 (CHCym), 80.5 
(C3/C5Cym), 81.3 (C2/C6Cym), 99.5 ( C4Cym), 100.9 (C1Cym), 119.4 (C3), 139.6 (C6), 
157.1 (C2), 166.0 (C5), 187.0 (C4); elemental analysis calcd (%) for 
C16H19ClO2RuS : C 46.65, H 4.65, S 7.78; found C 46.24, H 4.61, S 8.04.  
Chlorido[2-methyl-3-(oxo-κO)-pyran-4(1H)-thionato-κS](η6-p-cymene)-
ruthenium(II) (2h): The reaction was performed according to the general 
complexation protocol, using thiomaltol 1h (103 mg, 0.72 mmol, 1eq), NaOMe 
(43 mg, 0.8 mmol, 1.1 eq) and [Ru(η6-p-cymene)Cl2]2 (200 mg, 0.33 mmol, 0.45 eq). 
The crude product was recrystallized from ethyl acetate/n-hexane, affording a red 
crystalline solid (200 mg, 74%). Mp: > 190 °C (decomp.); 1H NMR (500.10 MHz, 
CDCl3):  = 1.28 (d, 3J(H,H) = 7 Hz, 6H, CH3,Cym), 2.21 (s, 3H, CH3,Cym), 2.50 (s, 
3H, CH3), 2.76 (m, 1H, CHCym), 5.49 (brs, 2H, H3/H5Cym); 5.71 (brs, 2H, H2/H6Cym), 
7.18 (d, 3J(H,H) = 5 Hz, 1H, H5), 7.43 (d, 3J(H,H) = 5 Hz, 1H, H6); 13C NMR 
(125.75 MHz, CDCl3):  = 15.4 (CH3), 18.4 (CH3,Cym), 22.1 (CH3,Cym), 31.0 (CHCym), 
80.5 (C3/C5Cym), 81.3 (C2/C6Cym), 98.2 (C4Cym), 100.0 (C1Cym), 120.2 (C5), 143.9 
(C6), 153.3 (C2), 165.4 (C3), 180.5 (C4); elemental analysis calcd (%) for 
C16H19ClO2SRu: C 46.65, H 4.65, S 7.75; found C 47.03, H 4.57,  S 7.67.  
pKa determination. For the pKa value determination, 2a–f were dissolved in D2O 
and the pH of the solution in the NMR tube was determined with an Eco Scan pH6 
pH meter equipped with a glass-micro combination pH electrode (Orion 9826BN) 
and calibrated with standard buffer solutions of pH 4.00, 7.00 and 10.00. The pH 
titration was performed by addition of NaOD (0.4–0.0004% in D2O) to a DNO3-
acidifed solution (0.4–0.0004% in D2O). The observed shifts of the H2/H6 cymene 
protons in the 1H NMR spectra were plotted against the pH value, and the obtained 
curves were fitted using the Henderson-Hasselbalch equation with Excel software 
(Microsoft® Office Excel 2003, SP3, Microsoft Corporation). The experimentally 
obtained pKa* values were corrected with equation 1,[48] in order to convert the pKa* 
in D2O to the corresponding pKa values in aqueous solutions.  
pKa = 0.929 pKa* + 0.42 (1) 
Computational details. The full geometry optimization of all structures has been 
carried out at the DFT level of theory using Becke’s three-parameter hybrid 
exchange functional[49] in combination with the gradient-corrected correlation 
functional of Lee, Yang and Parr[50] (B3LYP) with the help of the Gaussian-03[51] 
program package. Symmetry operations were not applied for all structures. The 
geometry optimization was carried out using a quasi-relativistic Stuttgart 
pseudopotential described 28 core electrons and the appropriate contracted basis set 
(8s7p6d)/[6s5p3d][52] for the ruthenium atom and the 6-31G(d) basis set for other 
atoms. Then single-point calculations were performed in the basis of the found 
equilibrium geometries using the 6-31+G(d,p) basis set for non-metal atoms. The 
experimental X-ray structure of 2h[34] was chosen as the starting geometry for the 
optimizations. The Hessian matrix was calculated analytically for all optimized 
structures in order to prove the location of correct minima (no “imaginary” 
frequencies), and to estimate thermodynamic parameters, the latter were calculated 
at 25 °C. 
Solvent effects were taken into account at the single-point calculations based on the 
gas-phase equilibrium geometries at the CPCM-B3LYP/6-31+G(d,p)//gas-
B3LYP/6-31G(d) level of theory using the polarizable continuum model in the 
CPCM version[53,54] with H2O as a solvent and UAKS atomic radii. The Gibbs free 
energies in solution (Gs) were estimated by addition of the solvation energy δGsolv to 
gas-phase Gibbs free energies (Gg). 
pKa values have been calculated for the reaction HA+ + H2O  A + H3O+ (HA+ – 
cationic complexes 3’b, 3’d, 3’g and 3’h, A – corresponding neutral hydroxo-
complexes 5’b, 5’d, 5’g and 5’h, 1 atm standard state) using equation 2. 
74.1
303.2

RT
GpK sa
 (2) 
The vertical heterolytic bond energies in solution have been calculated at the 
CPCM-B3LYP/6-31+G(d,p)//gas-B3LYP/6-31G(d) level of theory. 
Interaction with small biomolecules. Complexes 2a–h (1–2 mg/ml) were 
dissolved in D2O (containing 5% [D6]-DMSO for 2g and 2h), yielding the aqua 
species 3a–h, titrated with 5’-GMP solution (10 mg/mL) in 50 μL steps, and the 
reaction was monitored by 1H and 31P NMR spectroscopy until unreacted 5’-GMP 
was detected. 
For the investigation of the reactivity towards amino acids and imidazole, the aqua-
complexes 3a–h (1 mg/mL) were reacted with an equimolar amount of amino acid 
and the 1H NMR spectra were recorded after 5 min and 18 h.  
Cytotoxicity in cancer cell lines 
Cell lines and culture conditions. CH1 cells originate from an ascites sample of a 
patient with a papillary cystadenocarcinoma of the ovary and were a generous gift 
from Lloyd R. Kelland, CRC Centre for Cancer Therapeutics, Institute of Cancer 
Research, Sutton, UK. SW480 (adenocarcinoma of the colon, human), and A549 
(non-small cell lung cancer, human) cells were kindly provided by Brigitte Marian 
(Institute of Cancer Research, Department of Medicine I, Medical University of 
Vienna, Austria). All cell culture reagents were obtained from Sigma-Aldrich 
Austria. Cells were grown in 75 cm² culture flasks (Iwaki) as adherent monolayer 
cultures in Minimal Essential Medium (MEM) supplemented with 10% heat-
inactivated fetal calf serum, 1 mM sodium pyruvate, 4 mM L-glutamine and 1% non-
essential amino acids (100). Cultures were maintained at 37 °C in a humidified 
atmosphere containing 95% air and 5% CO2. 
MTT assay conditions. Cytotoxicity was determined by the colorimetric MTT (3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, purchased from 
Fluka) microculture assay. For this purpose, cells were harvested from culture flasks 
by trypsinization and seeded in 100 µL aliquots into 96-well microculture plates 
(Iwaki). Cell densities of 1.5 × 103 cells/well (CH1), 2.5 × 103 cells/well (SW480) 
and 4 × 103 cells/well (A549) were chosen in order to ensure exponential growth of 
untreated controls throughout the experiment. Cells were allowed to settle and 
resume exponential growth in drug-free complete culture medium for 24 h. Stocks 
of the test compounds in DMSO were appropriately diluted in complete culture 
medium such that the maximum DMSO content did not exceed 1% (this procedure 
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yielded opaque but colloidal solutions from which no precipitates could be 
separated by centrifugation). These dilutions were added in 100 µL aliquots to the 
microcultures (if necessary due to limited solubility, the maximum concentration 
tested was added in 200 µL aliquots after removal of the pre-incubation medium), 
and cells were exposed to the test compounds for 96 hours. At the end of exposure, 
all media were replaced by 100 µL/well RPMI1640 culture medium (supplemented 
with 10% heat-inactivated fetal bovine serum) plus 20 µL/well MTT solution in 
phosphate-buffered saline (5 mg/ml). After incubation for 4 h, the supernatants were 
removed, and the formazan crystals formed by vital cells were dissolved in 150 µL 
DMSO per well. Optical densities at 550 nm were measured with a microplate 
reader (Tecan Spectra Classic), using a reference wavelength of 690 nm to correct 
for unspecific absorption. The quantity of vital cells was expressed in terms of T/C 
values by comparison to untreated control microcultures, and 50% inhibitory 
concentrations (IC50) were calculated from concentration-effect curves by 
interpolation. Evaluation is based on means from at least three independent 
experiments, each comprising at least three replicates per concentration level. 
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1. Characterization of the complexes 2a and 2e by 1H NMR 
spectroscopy 
 
 
Figure S1: Geminal splitting of the CH2 group in the 1H NMR spectrum of 2e in CDCl3, due to the 
formation of a hydrogen bond between –OH and O3. 
 
 
 
Figure S2: Geminal splitting of the CH2 group in the 1H NMR spectrum of 2a in CDCl3, due to the 
formation of a hydrogen bond between –OH and O1. 
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2. Single crystal X-ray diffraction analysis data 
 
Table S1: Crystallographic data of 2a. 
Chemical formula 2a C16H19ClO4Ru 
M (g mol-1) 411.85 
Temperature (K) 100(2)  
Crystal size (mm3) 0.20 × 0.15 × 0.10 
Crystal color, shape red, block 
Crystal system monoclinic 
Space group P21/n 
a (Å) 10.7989(4) 
b (Å) 14.1722(8) 
c (Å) 21.0364(10) 
ß (°) 90.003(3) 
V (Å3) 3207.2(3) 
Z 8 
Dc (g cm-3) 1.706 
μ (cm-1) 11.58 
F(000) 1664 
θ range for data collection (°) 2.05–25.71 
h range -13/13 
k range -17/17 
l range -25/25 
No. refls. used in refinement 6091 
No. parameters 401 
Rint 0.1015 
R1a 0.0412 
wR2b 0.1107 
GOFc 1.001 
a R1 = Fo - Fc/Fo. 
b wR2 = {[w(Fo2 – Fc2)2]/w(Fo2)2]}1/2. 
c GOF = {[w(Fo2 – Fc2)2] /(n – p)}1/2, where n is the number of reflections and p is the total 
number of parameters refined. 
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Table S2: Crystallographic data of 2c. 
Chemical formula 2c C15H17ClO3Ru 
M (g mol-1) 381.81 
Temperature (K) 100(2)  
Crystal size (mm3) 0.18 × 0.16 × 0.12 
Crystal color, shape red, block 
Crystal system triclinic 
Space group P-1 
a (Å) 8.0776(7) 
b (Å) 8.4215(10) 
c (Å) 11.2342(14) 
α (°) 83.675(9) 
ß (°) 73.624(6) 
γ (°) 89.712(7) 
V (Å3) 728.48 
Z 2 
Dc (g cm-3) 1.741 
μ (cm-1) 12.63 
F(000) 384 
θ range for data collection (°) 2.43–25.70 
h range -9/9 
k range -10/10 
l range -13/13 
No. refls. used in refinement 2771 
No. parameters 182 
Rint 0.0643 
R1a 0.0271 
wR2b 0.0634 
GOFc 1.024 
a R1 = Fo - Fc/Fo. 
b wR2 = {[w(Fo2 – Fc2)2]/w(Fo2)2]}1/2. 
c GOF = {[w(Fo2 – Fc2)2] /(n – p)}1/2, where n is the number of reflections and p is the total 
number of parameters refined. 
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Table S3: Crystallographic data of 2d. 
Chemical formula 2d C16H19ClO3Ru 
M (g mol-1) 395.85 
Temperature (K) 296(2)  
Crystal size (mm3) 0.30 × 0.25 × 0.20 
Crystal color, shape red, block 
Crystal system monoclinic 
Space group P21/c 
a (Å) 11.8660(5) 
b (Å) 9.2496(4) 
c (Å) 15.5200(6) 
ß (°) 109.523(2) 
V (Å3) 1605.48(12) 
Z 4 
Dc (g cm-3) 1.638 
μ (cm-1) 11.49 
F(000) 800 
θ range for data collection (°) 2.61–26.42 
h range -14/14 
k range -11/11 
l range -19/19 
No. refls. used in refinement 3305 
No. parameters 190 
Rint 0.0534 
R1a 0.0355 
wR2b 0.0931 
GOFc 1.037 
a R1 = Fo - Fc/Fo. 
b wR2 = {[w(Fo2 – Fc2)2]/w(Fo2)2]}1/2. 
c GOF = {[w(Fo2 – Fc2)2] /(n – p)}1/2, where n is the number of reflections and p is the total 
number of parameters refined. 
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Figure S3: Syndiotactic chain formed by the R- and S-enantiomers of 2a. 
 
 
 
Figure S4: Layer structure of 2a in the crystal. 
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3. In vitro anticancer activity 
 
 
Figure S5: Concentration–effect curves of 3c in CH1 and SW480 cell lines. 
 
 
 
Figure S6: Concentration–effect curves of 3h in CH1 and SW480 cell lines. 
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Table S4: Solubility of 3a–h in PBS. 
Complex Solubility in PBS (mg/mL) 
3a > 10 
3b S1 > 10 
3c > 10 
3d S1 > 10 
3e > 10 
3f 5 
3g S1 < 1 a 
3h S1 < 1 a 
a in 1% DMSO/PBS solution: > 10 mg/mL. 
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4. pKa determination 
 
4.1. NMR titration 
 
Figure S7: Titration curves for the pKa determination by means of 1H NMR spectroscopy. 
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4.2. Computational details 
 
 
Figure S8. Equilibrium structures of the calculated pyrone complexes with numbering of selected 
atoms. Structures of the thiopyrone species are similar. 
 
 
Table S5. Total energies, enthalpies and Gibbs free energies for the gas-phase and H2O solution 
(Hartree) of the calculated structures. 
 Eg(6-31G*) Eg(6-31+G**) Es Hg Gg Gs 
H2O –76.408953 –76.433933 –76.445244 –76.384013 –76.406114 –76.417425 
H3O+ –76.689084 –76.707574 –76.880432 –76.650930 –76.673921 –76.846779 
Cl– –460.252233 –460.274726 –460.388702 –460.249873 –460.267256 –460.381232
2’d –1244.752725 –1244.785467 –1244.808913 –1244.528795 –1244.589480 –1244.612926
3’d –860.753112 –860.793688 –860.870726 –860.503495 –860.565452 –860.642490
5’d –860.334699 –860.375987 –860.401011 –860.099002 –860.160042 –860.185066
2’h –1567.725128 –1567.756490 –1567.779352 –1567.503125 –1567.566512 –1567.589374
3’h –1183.730680 –1183.769920 –1183.844267 –1183.482906 –1183.545901 –1183.620248
5’h –1183.306404 –1183.346214 –1183.370216 –1183.072593 –1183.135279 –1183.159281
2’b –1244.752547 –1244.785001 –1244.810377 –1244.528703 –1244.589490 –1244.614866
3’b –860.753388 –860.793873 –860.871775 –860.503809 –860.565338 –860.643240
5’b –860.334962 –860.375987 –860.402292 –860.099323 –860.159878 –860.186183
2’g –1567.724717 –1567.755941 –1567.780854 –1567.502724 –1567.565314 –1567.590227
3’g –1183.730836 –1183.769955 –1183.844913 –1183.483090 –1183.545807 –1183.620765
5’g –1183.305917 –1183.345628 –1183.371532 –1183.072164 –1183.134632 –1183.160536
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Table S6. Cartesian coordinates (Å) of the calculated equilibrium structures of the complexes. 
 
2’b 
Ru -1.151625 0.008824 -0.011704 
Cl -0.529393 2.337869 -0.011134 
O 3.941668 -0.150756 0.973138 
O 0.350649 -0.249553 1.414042 
O 0.559083 -0.245173 -1.247858 
C -2.257874 -1.525794 -1.124459 
H -1.829779 -2.141372 -1.909460 
C -2.175773 -1.957723 0.224155 
H -1.706814 -2.902648 0.473799 
C -2.818445 -0.250902 -1.461588 
C 1.545361 -0.198260 0.878599 
C -3.123316 0.218972 0.947565 
H -3.352854 0.924950 1.736720 
C -3.232982 0.614668 -0.423011 
H -3.527238 1.630929 -0.659553 
C 2.720385 -0.165406 1.585370 
C 1.642077 -0.218542 -0.572679 
H 2.801174 -0.138805 2.662921 
C -2.571788 -1.052529 1.257840 
C 2.937307 -0.230092 -1.158556 
H 3.037444 -0.248889 -2.237712 
C 4.048836 -0.181882 -0.362313 
C 5.469139 -0.148971 -0.830593 
H -2.819485 0.089184 -2.490771 
H -2.372576 -1.307805 2.293789 
H 5.966748 0.766294 -0.489553 
H 5.512981 -0.184888 -1.921247 
H 6.031111 -0.998978 -0.426422 
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2’d 
Ru 1.263322 0.694785 -0.519390 
Cl 1.374085 -0.465312 -2.629825 
O -0.416880 -4.063596 0.661424 
O 1.691882 -1.147331 0.357558 
O -0.675472 -0.156716 -0.366232 
C 0.514582 2.612129 0.215428 
H -0.525502 2.801025 0.462731 
C 1.386707 2.093188 1.216396 
H 1.025632 1.911221 2.222159 
C 0.960126 2.817668 -1.124385 
C 0.654991 -1.955006 0.333449 
C 3.150286 1.839025 -0.511609 
H 4.116683 1.451678 -0.811736 
C 2.270846 2.404604 -1.479495 
H 2.567746 2.416597 -2.522253 
C 0.716202 -3.293023 0.665089 
C -0.627787 -1.390052 -0.036275 
C 1.945719 -4.042041 1.044665 
C 2.686740 1.666359 0.826154 
C -1.772412 -2.236598 0.008715 
H -2.751390 -1.850441 -0.250400 
C -1.605752 -3.543512 0.347178 
H -2.395156 -4.284071 0.388949 
H 0.270580 3.164560 -1.884815 
H 3.305871 1.127837 1.536769 
H 2.810721 -3.388637 0.917558 
H 2.074586 -4.930063 0.414116 
H 1.907385 -4.378948 2.089088 
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2’g 
Ru -1.231863 -0.015157 0.007590 
Cl -0.680801 -1.222759 2.034205 
O 3.968665 -0.986851 -0.720975 
O 0.377358 -1.042998 -0.849886 
S 0.513373 1.524754 0.621406 
C -2.773611 1.547767 -0.079924 
H -2.692489 2.531021 0.371626 
C -2.293755 1.339614 -1.417663 
H -1.852753 2.162051 -1.969024 
C -3.285753 0.467857 0.678823 
C 1.588285 -0.647267 -0.580181 
C -2.805744 -1.071592 -1.187955 
H -2.726602 -2.079703 -1.578384 
C -3.305278 -0.848522 0.109910 
H -3.593579 -1.689516 0.729834 
C 2.694119 -1.386209 -0.959248 
C 1.849064 0.600079 0.103658 
H 2.645964 -2.341401 -1.462920 
C -2.279022 0.030414 -1.945517 
C 3.196325 0.981885 0.304096 
H 3.425140 1.914838 0.807563 
C 4.226396 0.175746 -0.102890 
C 5.687667 0.435654 0.076102 
H -3.576341 0.612269 1.712226 
H -1.806202 -0.160367 -2.903074 
H 6.148853 -0.346781 0.690023 
H 5.845213 1.399357 0.564910 
H 6.203869 0.442509 -0.891019 
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2’h 
Ru 1.311265 1.074878 -0.584596 
Cl 1.585380 0.268461 -2.853205 
O 0.199127 -4.111449 -0.092515 
O 1.756894 -0.889542 -0.016866 
S -0.923355 0.187195 -0.684385 
C 0.626566 3.105734 -0.092816 
H -0.381855 3.477768 -0.242354 
C 0.968193 2.454108 1.140894 
H 0.221299 2.332404 1.917449 
C 1.572633 3.203882 -1.140782 
C 0.832516 -1.800777 -0.152710 
C 3.210563 1.957615 0.218089 
H 4.157778 1.436866 0.303131 
C 2.875177 2.627813 -0.974360 
H 3.558666 2.608682 -1.815571 
C 1.151731 -3.148082 0.000793 
C -0.535299 -1.458826 -0.439011 
C 2.523238 -3.659617 0.274238 
C 2.238548 1.853998 1.272011 
C -1.485600 -2.508966 -0.497450 
H -2.530512 -2.298922 -0.697998 
C -1.079855 -3.797919 -0.329182 
H -1.713150 -4.674206 -0.378468 
H 1.288608 3.629337 -2.095956 
H 2.463328 1.255175 2.148550 
H 3.244729 -3.142351 -0.366324 
H 2.573882 -4.736334 0.093249 
H 2.820276 -3.464546 1.313727 
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3’b 
Ru 0.582223 1.957559 -0.498825 
O 0.859757 0.932151 -2.440570 
O 0.261203 -2.871958 1.328016 
O 1.598215 0.254869 0.097622 
O -1.006426 0.610536 -0.291805 
C -0.655681 3.696221 0.076705 
H -1.735105 3.675683 0.187099 
C 0.172687 3.307771 1.179375 
H -0.274819 3.026118 2.125950 
C -0.086422 3.994761 -1.181372 
C 0.769416 -0.719394 0.453009 
C 2.165405 3.512222 -0.271452 
H 3.229648 3.372889 -0.424125 
C 1.327409 3.875317 -1.353039 
H 1.754837 3.991263 -2.343935 
C 1.158750 -1.907428 1.013762 
C -0.641831 -0.517963 0.223457 
H 2.176894 -2.192962 1.242125 
C 1.576391 3.216503 0.995178 
C -1.539708 -1.555543 0.567148 
H -2.603353 -1.432255 0.399398 
C -1.055909 -2.716819 1.116914 
C -1.859491 -3.901326 1.539468 
H -0.721503 4.227425 -2.028778 
H 2.198614 2.831107 1.796408 
H 0.031021 0.494391 -2.708050 
H 1.484378 0.217220 -2.206498 
H -1.533103 -4.798667 1.001856 
H -2.920134 -3.736506 1.340989 
H -1.725601 -4.092836 2.610190 
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3’d 
Ru 0.542595 0.869164 -1.297307 
O 0.863722 -0.284744 -3.158545 
O 0.568095 -3.801425 0.917138 
O 1.675126 -0.716227 -0.592778 
O -0.946313 -0.558204 -0.966198 
C -0.821978 2.589070 -0.990829 
H -1.905151 2.527369 -0.973834 
C -0.080028 2.336034 0.210515 
H -0.601733 2.109000 1.133685 
C -0.149981 2.801675 -2.212459 
C 0.914244 -1.712020 -0.142083 
C 2.025665 2.517168 -1.070826 
H 3.104591 2.419233 -1.115509 
C 1.280326 2.747157 -2.248637 
H 1.791765 2.805761 -3.203994 
C 1.415848 -2.816790 0.517402 
C -0.502166 -1.616212 -0.367688 
C 2.844982 -3.079115 0.837987 
C 1.334853 2.299114 0.163227 
C -1.334745 -2.678081 0.071837 
H -2.406663 -2.648670 -0.085351 
C -0.749521 -3.734996 0.701903 
H -1.267748 -4.603953 1.087337 
H -0.712460 2.923592 -3.131534 
H 1.895782 2.020470 1.049194 
H 0.060002 -0.792540 -3.374001 
H 1.532081 -0.938949 -2.873121 
H 3.434668 -2.181570 0.643601 
H 3.242332 -3.898571 0.225732 
H 2.957788 -3.368209 1.888475 
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3’g 
Ru 0.891711 1.867919 -0.069241 
O 1.112943 1.254112 -2.194564 
O 0.175806 -3.340433 0.756447 
O 1.562461 -0.090642 0.117317 
S -1.245989 0.810892 -0.142065 
C 0.194553 3.956200 0.328314 
H -0.755764 4.388235 0.034662 
C 0.306125 3.230676 1.557622 
H -0.566547 3.104085 2.189322 
C 1.302562 4.012521 -0.544457 
C 0.675659 -1.050072 0.304048 
C 2.660789 2.711035 1.035862 
H 3.572769 2.173574 1.273274 
C 2.553539 3.413642 -0.177621 
H 3.384853 3.431570 -0.873982 
C 1.063216 -2.340567 0.604473 
C -0.734966 -0.804650 0.187702 
H 2.088180 -2.664877 0.727965 
C 1.523602 2.596558 1.903909 
C -1.623690 -1.886282 0.354426 
H -2.693838 -1.735548 0.265433 
C -1.147747 -3.144263 0.638183 
C -1.953464 -4.381942 0.847623 
H 1.197398 4.476450 -1.519618 
H 1.585393 1.994175 2.803528 
H 0.240101 1.020195 -2.563044 
H 1.591518 0.407967 -2.087381 
H -1.664439 -5.156755 0.128522 
H -3.017475 -4.169394 0.727863 
H -1.785476 -4.785803 1.852600 
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3’h 
Ru 0.417749 1.437329 -0.680957 
O 0.690447 0.616449 -2.732596 
O -0.353340 -3.657867 0.631411 
O 1.066015 -0.499848 -0.284624 
S -1.720534 0.389320 -0.716314 
C -0.337352 3.517909 -0.403714 
H -1.318483 3.886937 -0.682231 
C -0.140818 2.892866 0.870979 
H -0.976230 2.782742 1.553723 
C 0.724806 3.554930 -1.331917 
C 0.165310 -1.433785 -0.029450 
C 2.209943 2.427504 0.272977 
H 3.156077 1.951336 0.506673 
C 2.013185 3.027914 -0.982714 
H 2.808169 3.021037 -1.720745 
C 0.564343 -2.692832 0.417590 
C -1.230471 -1.190308 -0.215629 
C 1.968525 -3.116537 0.666736 
C 1.117229 2.334539 1.198702 
C -2.140883 -2.246358 0.023592 
H -3.207721 -2.109826 -0.114418 
C -1.662220 -3.452238 0.441511 
H -2.251814 -4.332234 0.662687 
H 0.557153 3.944916 -2.330248 
H 1.244199 1.800222 2.134027 
H -0.177494 0.357521 -3.096427 
H 1.154013 -0.220284 -2.529789 
H 2.397713 -3.596155 -0.223470 
H 2.010656 -3.837722 1.487722 
H 2.581348 -2.244516 0.903923 
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5’b 
Ru 0.683632 1.979794 -0.451454 
O 1.099876 1.003903 -2.139870 
O 0.179014 -2.893896 1.426807 
O 1.584894 0.312634 0.496917 
O -0.977948 0.602034 -0.262145 
C -0.592273 3.650685 0.211440 
H -1.645597 3.563932 0.459592 
C 0.381234 3.485088 1.228659 
H 0.082130 3.284210 2.251122 
C -0.212934 3.867057 -1.155469 
C 0.750186 -0.679461 0.682441 
C 2.155258 3.589879 -0.515356 
H 3.193761 3.466585 -0.799386 
C 1.161739 3.839431 -1.504493 
H 1.446715 3.865595 -2.550881 
C 1.082714 -1.881468 1.256548 
C -0.638006 -0.504099 0.262168 
H 2.067194 -2.148317 1.615219 
C 1.745697 3.379812 0.841211 
C -1.538169 -1.589686 0.473093 
H -2.573006 -1.489642 0.165633 
C -1.098145 -2.751460 1.043201 
C -1.920933 -3.973038 1.306713 
H -0.971381 3.949199 -1.925435 
H 2.486106 3.075219 1.574262 
H 1.410027 0.124844 -1.865273 
H -1.522610 -4.834383 0.757746 
H -2.956037 -3.810520 0.998537 
H -1.906397 -4.227973 2.372724 
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5’d 
Ru 0.666795 0.911335 -1.291045 
O 1.192454 -0.092283 -2.930925 
O 0.478820 -3.898491 0.789796 
O 1.663356 -0.647456 -0.257866 
O -0.889001 -0.575433 -1.081271 
C -0.744957 2.502950 -0.714590 
H -1.792844 2.343760 -0.479684 
C 0.219501 2.452611 0.322782 
H -0.082047 2.267869 1.347580 
C -0.358573 2.695025 -2.083365 
C 0.896989 -1.692115 -0.041895 
C 2.011859 2.628574 -1.396816 
H 3.062027 2.578196 -1.659564 
C 1.020017 2.760870 -2.410226 
H 1.321306 2.768726 -3.452336 
C 1.326847 -2.836856 0.600918 
C -0.484192 -1.631283 -0.499489 
C 2.696633 -3.070763 1.137627 
C 1.595034 2.438856 -0.039656 
C -1.315192 -2.768421 -0.261548 
H -2.347620 -2.767258 -0.591990 
C -0.788119 -3.851241 0.368876 
H -1.321800 -4.767922 0.589289 
H -1.107305 2.688597 -2.867089 
H 2.343197 2.223576 0.716819 
H 1.530155 -0.948833 -2.620310 
H 3.299705 -2.177086 0.967567 
H 3.180502 -3.922445 0.642197 
H 2.672427 -3.285990 2.213557 
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5’g 
Ru 0.830690 1.932275 -0.040419 
O 0.620333 1.601591 -2.006970 
O 0.307819 -3.408883 0.486267 
O 1.558715 -0.066380 0.060701 
S -1.289649 0.775911 0.272915 
C 0.457922 4.105144 0.051779 
H -0.348833 4.626441 -0.449840 
C 0.255253 3.529133 1.348452 
H -0.718093 3.618902 1.820949 
C 1.696772 3.886108 -0.610550 
C 0.725490 -1.044480 0.236396 
C 2.481787 2.545756 1.296018 
H 3.213371 1.860826 1.713044 
C 2.715871 3.109819 -0.002236 
H 3.616506 2.860868 -0.551022 
C 1.151180 -2.362219 0.304196 
C -0.703037 -0.825378 0.374024 
H 2.182077 -2.673839 0.207255 
C 1.291112 2.815684 2.013669 
C -1.533646 -1.953220 0.575746 
H -2.604602 -1.820820 0.686180 
C -1.012687 -3.219871 0.623483 
C -1.774642 -4.491827 0.815314 
H 1.812018 4.203798 -1.641492 
H 1.113124 2.360399 2.981140 
H 0.114964 0.782002 -2.128312 
H -1.639777 -5.161203 -0.042544 
H -2.840537 -4.282109 0.929070 
H -1.425821 -5.026047 1.706951 
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5’h 
Ru 0.586766 1.401966 -0.737999 
O 1.161099 0.539890 -2.459334 
O -0.497575 -3.664910 0.695515 
O 1.032362 -0.476585 0.155264 
S -1.570701 0.330685 -1.049646 
C -0.340369 3.314239 -0.204793 
H -1.406692 3.515194 -0.242256 
C 0.236906 2.833924 1.005978 
H -0.379420 2.666573 1.881835 
C 0.448075 3.507798 -1.383820 
C 0.129896 -1.410170 0.154133 
C 2.398260 2.575537 -0.191770 
H 3.414865 2.200393 -0.209466 
C 1.819579 3.130338 -1.360432 
H 2.391414 3.147414 -2.282199 
C 0.431647 -2.676953 0.660814 
C -1.199833 -1.194614 -0.362378 
C 1.766527 -3.062556 1.196818 
C 1.581829 2.395921 0.975006 
C -2.127104 -2.263332 -0.277679 
H -3.142656 -2.141482 -0.638768 
C -1.741089 -3.460745 0.245505 
H -2.361684 -4.341978 0.343293 
H -0.011336 3.854014 -2.302090 
H 1.994052 1.872718 1.832124 
H 0.550442 -0.188740 -2.655542 
H 1.955146 -2.587083 2.168868 
H 2.552673 -2.715310 0.518225 
H 1.833934 -4.146706 1.318228 
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5. Reactions of complexes 3a–h with amino acids 
 
 
 
Figure S9: 1H NMR spectra of the reaction products 4a–h obtained by the incubation of 3a–h with 
equimolar amounts of glycine after 18 h. 
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Figure S10: 1H NMR spectra after 18 h of the reactions of 3a–h with an equimolar amount of L-
histidine. 
 
 
99
S26 
 
 
Figure S11: (a) Se-Methyl-L-selenocysteine, (b) 3b and (c) the reaction of 3b with an equimolar 
amount of Se-methyl-L-selenocysteine after 18 h. 
 
 
 
 
Figure S12: 13C NMR spectrum of 3b with an equimolar amount of Se-methyl-L-selenocysteine 
measured after 18 h. 
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6. The reaction of 3h with amino acids 
 
6.1. Glycine with an equimolar amount of 3h 
 
Figure S13: a) Glycine, b) 3h, c) 3h + 1 eq glycine after 5 min and d) after 18 h. 
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6.2. L-Histidine with an equimolar amount of 3h 
 
Figure S14: a) L-Histidine, b) 3h, c) 3h + 1 eq L-histidine after 5 min and d) after 18 h. 
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6.3. L-Methionine with an equimolar amount of 3h 
 
Figure S15: a) L-Methionine, b) 3h, c) 3h + 1 eq L-methionine after 5 min and d) after 18 h. 
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6.4. L-Cysteine with an equimolar amount of 3h 
 
Figure S16: a) L-Cysteine, b) 3h, c) 3h + 1 eq L-cysteine after 5 min, d) 3h + 1 eq L-cysteine after 
18 h. 
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 4. Conclusion and Outlook 
 
Within this PhD thesis a series of novel pyrone and thiopyrone derived Ru(II) p-cymene com-
plexes has been synthesized and their behavior in aqueous solution and reactivity towards 
small biomolecules was investigated. The cytotoxic activity in different human cancer cell 
lines was determined and structure-activity relationships were established.  
 
Organometallic 2-hydroxymethylaryl-5-hydroxy-6-methyl-pyran-4(1H)-one derived Ru(II) 
cymene complexes were prepared, which hydrolyzed quick to form the charged aqua species 
by replacing the chlorido ligand by a water molecule. The more reactive aqua complex was 
found to be stable in solution for more than 18 h and in the presence of nucleophilic agents 
like 5’-GMP, selective binding over the N7 of the purine ring was observed. Furthermore, the 
pKa values (8.99–9.64) of the compounds were determined by means of 1H NMR spectros-
copy. These values implicate that the complexes are present as more reactive aqua species 
under physiological conditions. The compounds exhibit moderate cytotoxic activity and were 
found to be more active against CH1 cells (ovarian cancer cell line) than against SW480 (co-
lon carcinoma) or A549 (non-small lung cancer) cells. The aryl moiety seems to be relevant 
for cytotoxic activity, because electron withdrawing groups decreased the IC50 value in con-
trast to electron donating groups.  
 
The effect of thiopyrone coordination on the cytotoxic activity and on the behavior in aqueous 
solution was investigated. The aquation behavior of the thiopyrone complexes was found to 
be quite different to that of the earlier reported maltol complex. In contrast to the maltol com-
plex, no formation of the dimeric species [Ru2(p-cymene)2(OH)3]+ was observed. This side 
reaction was supposed to be responsible for the minimal activity of the substance. DFT calcu-
lations have been performed to explain the observed results. The replacement of the chlorido 
ligand by an imidazole molecule prevents the dimer formation of the pyrone complexes The 
organometallic thiopyrone compounds were found to be by an order of magnitude more cyto-
toxic compared to the pyrone analogues and slightly more active in SW480 cells as compared 
to CH1 cells, though the latter are in general more chemosensitive to the majority of metal-
based and other tumor-inhibiting compounds tested so far. Furthermore, the behavior in aque-
ous solution and the interaction with small biomolecules like 5’-GMP and amino acids was 
assayed. It was found, that the observed Ru dimer [Ru2(p-cymene)2(OH)3]+ could not be the 
main factor for the minimal activity of the pyrone complexes, because the formation of the 
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 dimeric species can also be inhibited by modification of the substitution pattern of the pyrone 
scaffold. Replacement of the chlorido ligand by imidazole was shown to be an effective addi-
tional option to obtain in aqueous solutions stable Ru(II)–(p-cymene)(pyrone) complexes. 
Therefore, the interactions of the amino acids Gly, L-His, L-Met and L-Cys were investigated 
and it was observed, that the pyrone ligands of the corresponding complexes were cleaved off 
and the amino acid was bound in a bidentate manner within 18 h. In contrast, the pyrone 
compounds, the thiopyrone complexes formed quickly adducts with L-His and L-Met and 
were stable in solution for more than 18 h. The reaction with L-Cys led to fast decomposition 
and Gly did not coordinate to the metal center. This feature gives the thiopyrone complexes 
more time to be taken up into the tumor cells, whereas the pyrone complexes decompose to 
compound mixtures involving amino acid coordination. These results have important implica-
tions on the mode of action of the compounds and considerably active thiopyrone vs. mini-
mally active pyrone complexes were obtained. 
 
Further research will be on the synthesis of thiopyrones and on the evaluation of their anti-
cancer potential. The cellular uptake of these compounds should be investigated to get a dee-
per insight into the relationship between cytotoxic activity and cellular uptake. The change of 
the metal center and derivatization of the arene moiety is another direction opening interesting 
opportunities. Another possibility is the exchange of the chlorido ligand by more strongly 
coordinating ligands to prevent hydrolysis and cleavage of the pyrone in aqueous solution and 
investigations on the cytotoxic activity of this class of compounds. With regard to studies on 
the mode-of-action at the molecular level, the interactions with oligonucleotides and proteins 
will be investigated.  
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